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In consideration of new data and the availa-
bility of an additional vaccine for adults, the 
German Standing Committee on Vaccina-
tion (STIKO) has updated its recommen-
dation for the routine vaccination of older 
adults against pneumococcal diseases.
Updated recommendation
Routine vaccination is recommended for 
all adults from the age of 60 years. Vacci-
nation shall be given with a vaccine of the 
greatest possible efficacy against the pneu-
mococcal serotypes currently causing dis-
ease in the target group; this is current-
ly the 23-valent polysaccharide vaccine 
(PPSV23).
In principle, because of the limited 
duration of protection provided by the 
vaccine, STIKO considers repeated vac-
cinations with PPSV23 useful from a 
medico-epidemiological perspective. The 
current prescribing information specifies 
that “healthy adults should not routinely 
be re-vaccinated”, i. e. routine re-vaccina-
tion is not covered by the market author-
ization. However, according to the pre-
scribing information “re-vaccination may 
be considered for persons at increased risk 
for severe pneumococcal disease”. In this 
case STIKO recommends a minimum in-
terval of 6 years between vaccine doses.
Seniors who belong to one of the risk 
groups listed in table 2 of the STIKO rec-
ommendations because of a chronic con-
dition (category “I”) or because of occupa-
tional exposure (category “B”) should be 
vaccinated according to the specific rec-
ommendations for these groups.
Seniors who have already been vacci-
nated with the 13-valent conjugate vaccine 
(PCV13) should receive a follow-up vac-
cination with PPSV23 6–12 months after 
PCV13 to expand serotype coverage.
The objective of the vaccination recom-
mendation is to reduce the number of cas-
es of invasive pneumococcal disease and 
pneumococcal pneumonia and their con-
sequences, such as hospitalization, disabil-
ity, and death among older adults in Ger-
many.
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The incidence of pneumococcal diseases among adults increases with age. Therefore, Germany’s Standing Committee on Vaccination (Ständige 
Impfkommission, STIKO) has since 1998 recommended vaccination with the 23-valent pneumococcal polysaccharide vaccine (PPSV23) for all people aged 
≥60 years. PPSV23 has been the only pneumococcal vaccine licensed for adults until few years ago. Universal pneumococcal vaccination of infants, using 
a conjugate vaccine, has been recommended by STIKO since 2006. Since then, pneumococcal serotypes contained in conjugate vaccines have declined 
among cases of pneumococcal disease not only in children, but – through herd protection – also in older adults. The 13-valent pneumococcal conjugate 
vaccine (PCV13), currently used for most infants in Germany, has now been approved for use in adults as well. Data on the efficacy of PCV13 against clinical 
endpoints in older adults was published in 2015. For that reason, STIKO investigated whether one of the two vaccines (or the combination of both) should 
be preferred in order to reduce the burden of pneumococcal diseases in older adults, and at what age the vaccine should be given.
Efficacy against invasive pneumococcal diseases
Pooled data from 4 randomised controlled trials (RCTs) of PPSV23 in older adults show an efficacy of 73 % against invasive pneumococcal disease (IPD) 
caused by any serotype (95 % confidence interval [CI], 10–92 %). The IPD cases in these studies were mostly caused by one of the 23 serotypes contained in 
the vaccine. The efficacy of PCV13 in older adults was investigated in one RCT. Efficacy against IPD by any serotype was 49 % (95 % CI, 21–67 %, modi-
fied-intention-to-treat analysis). Efficacy against IPD by the 13 serotypes contained in the vaccine (VT-IPD) was 76 % (95 % CI, 47–90 %).
Efficacy against pneumococcal pneumonia
After exclusion of 2 RCTs with a high risk of bias, pooled efficacy of PPSV23 against pneumococcal pneumonia (PP) caused by any serotype in the 
remaining 2 RCTs was 64 % (95 % CI, 35–80 %). In the included observational studies, pooled efficacy ranged from 37 % to 53 %, with broadly overlapping 
CIs, depending on study type. The efficacy of PCV13 against PP caused by any serotype was 22 % (95 % CI, 2–39 %), and against VT-PP it was 38 % (95 % CI, 
14–55 %).
Anticipated epidemiological and health economic effects
The above-mentioned studies do not provide clear evidence of a difference between the two vaccines regarding efficacy against clinical endpoints 
(IPD, PP) caused by the serotypes contained in the respective vaccine. In the 2015-’16 season, 70 % of IPD cases in people aged ≥60 years were caused 
by PPSV23 serotypes, but only 30 % by PCV13 serotypes. Because PPSV23 contains all the serotypes in PCV13 (except for serotype 6A), vaccination with 
PPSV23 confers broader serotype coverage and can thereby prevent considerably more cases.
The estimated effects of various vaccination strategies were compared using a dynamic transmission model. Because the protection the vaccines provide 
is limited to a few years, the effects of a one-time vaccination (e. g. at age 60) are minor. Administering a one-time vaccination with PPSV23 to 30 % (which 
is the current vaccination uptake in Germany) of people turning 60 in 2016–2020 could prevent a cumulative estimate of 2,253 hospitalisations and 270 
deaths from pneumococcal diseases in the remaining lifespan (about 25 years). A one-time vaccination with PCV13 alone, however, would prevent only 
725 hospitalisations and 101 deaths. Compared with vaccination with PPSV23 only, sequential vaccination with PCV13 and PPSV23 could prevent an 
additional 296 hospitalisations and 47 deaths in this period (about 25 years). Observing a longer period of time for this vaccination strategy (e. g. people 
who turn 60 in 2016–2030) would further diminish the benefit of the additional PCV13 vaccination because the model predicts a continued marked 
reduction in PCV13 serotypes over the coming years.
A vaccination strategy with repeated PPSV23 vaccinations every 6 years leads to markedly better results. Vaccinating 30 % of people turning 60 in 
2016–2020, with initial and re-vaccinations with PPSV23, could prevent a cumulative estimate of 22,169 hospitalisations and 4,272 deaths over those 
people’s lifetimes. Initial vaccination with PCV13 and PPSV23 (with re-vaccinations with PPSV23 only), would further prevent an additional 72 hospitalisa-
tions and 10 deaths only over this time span.
For a one-time vaccination with PPSV23, the number needed to vaccinate (NNV) is 801 to prevent a hospitalisation and 6,609 to prevent a death. For 
a sequential vaccination strategy, the NNV of PCV13 in addition to PPSV23 is 6,072 to prevent an additional hospitalisation and 38,024 to prevent an 
additional death. For the vaccination strategy with initial and re-vaccinations every 6 years with PPSV23, the NNV is considerably lower than for a one-time 
vaccination (398 per hospitalisation prevented and 2,064 per death prevented) because the disease incidence rises with age. If the initial vaccination is 
sequential (PCV13 + PPSV23) and the re-vaccinations are with PPSV23, an additional 25,000 older adults must be vaccinated with PCV13 to prevent an 
additional hospitalisation and 167,000 to prevent an additional death.
The costs of the vaccination strategy with initial and re-vaccinations with PPSV23 alone are € 12,800 per quality-adjusted life year (QALY) gained and 
€ 6,700 per hospitalisation prevented. If the initial vaccination is sequential (PCV13 + PPSV23), the costs are about € 2,800,000 per QALY gained and 
€ 1,500,000 per additional hospitalisation prevented (. Table 11).
Conclusion
Based on these findings, STIKO continues to recommend vaccination with PPSV23 for all adults at age 60 years. STIKO also considers re-vaccinations in 
intervals of ≥6 years to renew vaccine protection useful for medical and epidemiological reasons. 
According to the market authorisation of PPSV23 repeated vaccinations are only indicated for “persons with an elevated risk for severe pneumococcal 
diseases”. Therefore, the indication for re-vaccination should be assessed on an individual basis. Patients should be counselled not only on the increased 
reactogenicity of re-vaccinations compared with first-time vaccinations, but also about the risk of losing protection without re-vaccination.
Sequential vaccination with PCV13 and PPSV23 is not recommended as a standard vaccination for older adults because of the low number of additional 
preventable cases and the very high NNV.
People with certain underlying diseases, in particular immunocompromising conditions, can benefit from a sequential vaccination (PCV13 followed 
by PPSV23). For more information, please see the STIKO recommendation on indication-based vaccination against pneumococci in Epidemiologisches 
Bulletin 37/2016 at www.rki.de (in German).
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Scientific rationale
1. Pathogen and clinical presenta-
tion
Pneumococci (Streptococcus pneumoniae) 
are gram-positive encapsulated bacteria. 
The polysaccharide capsule is a critical vir-
ulence factor because it prevents phagocy-
tosis of the pathogen. The antigenic prop-
erties of the capsule polysaccharides allow 
over 90 serotypes to be distinguished, 
while even more serotypes are still being 
discovered [1]. Related serotypes are clus-
tered into serogroups. Some serogroups 
exhibit cross-immunity among the vari-
ous serotypes belonging to the same se-
rogroup; these include serogroup 6 with 
the epidemiologically important serotypes 
6A and 6B. But there are also serogroups 
with no cross-immunity of mention be-
tween serotypes; e. g. between serotypes 
19A and 19F [2, 3].
Pneumococci colonise the human na-
sopharynx, usually without causing symp-
toms. However, through local spread they 
can cause diseases of the upper (sinusi-
tis, middle ear inflammation) and low-
er (pneumonia) respiratory tract [4]. In-
vasive pneumococcal diseases (IPDs) are 
particularly serious. They are defined as 
the isolation of pneumococci from nor-
mally sterile body fluids. The most com-
mon forms of IPD are bacteraemia (ver-
ified by blood culture) and meningitis 
(detection in cerebrospinal fluid). Far less 
often are pneumococci found in pleural, 
joint, or ascites taps. Different serotypes 
exhibit different levels of ability to cause 
invasive diseases [5].
The most common forms of pneumo-
coccal (Pnc) diseases in adults are com-
munity-acquired pneumonia (CAP) and 
IPD. In adults, IPD manifests mostly as 
pneumococcal pneumonia with concom-
itant bacteraemia. A clear delineation be-
tween the two manifestation forms is not 
possible. Presumably, many IPD cases 
are misssed because often no blood cul-
tures are performed during the diagnostic 
work-up of a CAP case, or because they 
show up false negative; e. g. in patients 
who have already started antibiotic treat-
ment [4].
2. Epidemiology
Pneumococci are transmitted by drop-
let infection from person to person. 
Small children with asymptomatic na-
sopharyngeal colonisation are the ep-
idemiologically most important path-
ogen reservoir. No representative data 
are available on the prevalence of naso-
pharyngeal (NP) carriers in Germany. A 
cross-sectional study conducted in Eng-
land in 2012–’13, 6 years after universal 
vaccination of infants with pneumococ-
cal conjugate vaccine (PCV) was intro-
duced, found the prevalence of NP car-
riers to be 48 % among children aged <5 
years, 22 % among ages 5–20 years, and 
3 % among ages >20 years. Although the 
overall prevalence of NP carriers was 
similar to that in 2001–’02 (before uni-
versal vaccination of infants was intro-
duced), the percentage of carriers of the 
serotypes contained in the currently used 
PCV13 vaccine dropped from over 75 % 
to around 5 % in that period [6].
Incidence of IPD
In Germany there is no nationwide man-
datory reporting of pneumococcal diseas-
es. The states of Saxony-Anhalt, Saxony, 
Mecklenburg-Vorpommern, Branden-
burg, and Thuringia each have a state-
wide reporting obligation for IPD. High-
er incidence is reported among children 
aged <2 years, and older adults (. Fig. 1). 
No conclusions on actual IPD incidence 
can be drawn from these reporting data 
because the extent of underreporting is 
unknown. Reasons for underreporting 
are insufficient diagnostics (blood cul-
tures) and possible noncompliance with 
reporting obligations. 
Since 1997, the Robert Koch Institute 
(RKI) in Berlin has been conducting vol-
untary, laboratory-based sentinel surveil-
lance for IPD cases. Until 2006, only IPD 
cases in children were recorded. In con-
nection with the recommendation for uni-
versal vaccination of children, this sur-
veillance was expanded with the online 
PneumoWeb (www.rki.de/pneumoweb) 
in 2007 to include people of all ages. The 
primary aim of PneumoWeb is to moni-
tor the effects of vaccination on serotype 
distribution in IPD cases in all age groups 
(see Sect. 4). In addition to the anticipated 
reduction in vaccine serotypes, the extent 
of a potential serotype replacement should 
also be tracked. Serotype replacement is 
understood as an increase in serotypes not 
contained in the vaccine that fill the gap 
left by the reduction in vaccine serotypes. 
Consequently, the vaccination’s effect on 
the overall incidence of IPD can be lower 
than what could be anticipated, based on 
Fig. 1 8 Incidences of invasive pneumococcal diseases (IPD) reported in the German federal states 
of Brandenburg, Saxony, Saxony-Anhalt, and Mecklenburg-Vorpommern, average of the years 
2011–2015, by age  
Source: Mandatory case reporting according to State Regulations. Data from Thuringia not included 
because the reported incidence is only about one tenth of that in the other states, which certainly 
does not reflect the real situation
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the vaccine’s efficacy against the serotypes 
contained within [7].
The actual incidence of IPDs cannot 
be determined from PneumoWeb data 
because only some of the clinical micro-
biological laboratories in Germany par-
ticipate voluntarily in the surveillance. 
Furthermore, the size of the catchment 
population of the participating labora-
tories and the clinics they serve is not 
known. Assuming that nearly all IPD cases 
are treated on an inpatient basis, hospital 
diagnosis statistics offer a better indication 
of the incidence of IPD cases diagnosed in 
Germany (see Sect. 6.1, . Table 1).
Incidence of pneumococcal pneu-
monia
Germany has no surveillance system in 
place that allows estimation of the inci-
dence of pneumococcal pneumonia. We 
therefore conducted an exploratory liter-
ature search of reviews of studies on the 
incidence of pneumococcal pneumonia 
in Europe, and linked the findings to data 
from the German CAPNETZ study [8] 
and official hospital diagnosis statistics 
(www.gbe-bund.de) (see Sect. 6.1).
3. Pneumococcal vaccines
As early as the 1930s, Kaufman proved in 
a major clinical trial, with around 11,000 
participants, that humans can be immu-
nised against a pneumococcal infection 
through an injection of polysaccharide 
components of the pneumococcal cap-
sule [9]. Industrially produced vaccines 
against pneumococci have been availa-
ble since the 1970s, initially in the form 
of a 14-valent pure pneumococcal poly-
saccharide vaccine (PPSV14) with 50 µg 
of capsule polysaccharide per serotype [2]. 
This was replaced in 1983 by the 23-valent 
polysaccharide vaccine (PPSV23), which 
is still on the market. PPSV23 consists of 
25-µg capsule polysaccharides of each of 
the serotypes that were epidemiologically 
most important at that time (1, 2, 3, 4, 5, 
6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 
17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F), 
and contains no adjuvant [4].
Unlike in adults, polysaccharide vac-
cines exhibit low immunogenicity in chil-
dren aged <2 years, a group with high 
incidence of IPD [4]. This led to devel-
opment of pneumococcal conjugate vac-
cines (PCVs), in which the polysaccharide 
antigens are bonded to a carrier protein, 
resulting in a marked improvement in 
immunogenicity in infants and young 
children. But the production process is 
more complex; therefore, the first licensed 
conjugate vaccine (PCV7) contained only 
the antigens of the seven most common 
serotypes at that time: 4, 6B, 9V, 14, 18C, 
19F, and 23F. In February 2001, PCV7 was 
licensed in the European Union for chil-
dren aged ≤5 years.
In late 2009, PCV7 was replaced by 
PCV13, which contains the addition-
al serotypes 1, 3, 5, 6A, 7F, and 19A. In 
subsequent years, market authorisation 
was gradually expanded to include older 
age groups, and in July 2013, PCV13 was 
authorised for all age groups ≥6 weeks. 
Since 2009, an additional 10-valent con-
jugate vaccine (PCV10, Synflorix®) has 
been available for children aged ≤5 years. 
It contains serotypes 1, 5, and 7F, in addi-
tion to the PCV7 serotypes. The conjugate 
vaccines contain 1–3 µg (PCV10) or 2.2–
4.4 µg (PCV7, PCV13) polysaccharide of 
each serotype, and aluminium phosphate 
as an adjuvant.
All serotypes in PCV13 are also pres-
ent in PPSV23, with the exception of 6A. 
However, PPSV23 likely provides partial 
protection against serotype 6A because of 
cross-immunity with serotype 6B, which 
the vaccine contains [2, 3, 10].
Protection from nasopharyngeal col-
onisation with pneumococci of the sero-
types contained in a PCV vaccine has been 
credibly documented. Therefore, routine 
PCV vaccination in childhood results in 
herd protection. Regarding PPSV, how-
ever, a review article from 2012 reported 
that this vaccine led to a reduction in na-
sopharyngeal colonisation with serotypes 
contained in the vaccine in only one of 
four studies cited [10, 11].
4. Current STIKO recommendations 
for pneumococcal vaccination
In 1998, STIKO first recommended pneu-
mococcal vaccination with a polysaccha-
ride vaccine for people aged ≥60 years 
(called “senior vaccination”), with repeat 
vaccination after 6 years [12]. In 2009, the 
recommendation for repeat vaccinations 
was restricted to certain risk groups; with 
a one-time vaccination recommended as 
the standard for older adults. A number of 
reports of severe local reactions, and con-
tradictory evidence in the medical litera-
ture regarding poorer antibody responses 
after repeat vaccinations, were the reasons 
for this change [13]. Since then, several 
further studies have been published, ne-
cessitating a reassessment of these issues.
In addition, STIKO recommends 
pneumococcal vaccination for children, 
adolescents, and adults at increased risk 
because of an underlying disease (table 2 
in the STIKO recommendations). Since 
2006, STIKO has additionally recom-
mended universal vaccination with pneu-
mococcal conjugate vaccine for all infants.
The primary aim of universal vaccina-
tion during infancy is reducing the burden 
of invasive pneumococcal disease includ-
ing complications, such as hospitalisation, 
disability, and death, in this age group. 
Furthermore, a reduction in asympto-
matic nasopharyngeal colonisation in 
vaccinated children, and an associated re-
duction in the IPD disease burden in (un-
vaccinated) people in higher age groups 
through herd protection were also antici-
pated [14]. STIKO had not defined an ex-
plicit objective for the senior vaccination; 
that is part of this update. 
Implementation 
The vaccination status of adults was re-
corded as part of the “Study of the Health 
of Adults in Germany” (Studie zur Ge-
sundheit Erwachsener in Deutschland, 
DEGS), conducted by the RKI from 2008 
to 2011 [15]. Pneumococcal vaccination 
uptake among participants aged 65–79 
years was 31.4 % (95 % CI, 28.1–34.9 %); 
slightly higher in women (33.2 %) than in 
men (29.3 %). Vaccination uptake was sig-
nificantly higher in the former East Ger-
many, both in women (57.9 %) and men 
(49.7 %), than in the former West Germa-
ny (women, 27.2 %; men, 24.6 %). 
Serotype distribution since intro-
duction of universal infant vacci-
nation 
PneumoWeb data (. Fig. 2 and 3) show 
that the percentage of serotypes contained 
in the conjugate vaccines among all IPD 
cases has dropped substantially since the 
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recommendation of universal infant vac-
cination. That drop applies not only to the 
target age group of young children, but 
to all age groups; in other words, the an-
ticipated herd protection has occurred. 
Among ≥60 year olds, the percentage 
of PCV13 serotypes among IPD cases 
dropped from about 75 % when univer-
sal infant vaccination was introduced in 
2007 to 30 % in the 2015–’16 season. To 
the contrary, the percentage of IPD cas-
es caused by PPSV23 serotypes was about 
70 % in 2015–’16. . Fig. 2 shows the rel-
ative percentage of the respective vaccine 
serotypes. . Fig. 3 shows the absolute case 
numbers for people aged ≥60 years.
Serotype (ST) 3 is a special case; it be-
longs to the six additional serotypes con-
tained in PCV13 that are not included 
in PCV7. While the case numbers of the 
other PCV13 serotypes have steadily de-
creased since 2007, cases by ST 3 have in-
creased. In the last two seasons, ST 3 was 
by far the most common serotype, caus-
ing almost 20 % of all IPD cases in peo-
ple aged ≥60 years (. Fig. 3). Unlike the 
other five additional serotypes in PCV13, 
its percentage among IPD cases in Ger-
many did not drop after the switch from 
PCV7 to PCV13, in either children or old-
er adults (see . Fig. 4 and [16]). A similar 
phenomenon has been observed in other 
countries [17–19].
PCV13 thus appears to provide little or 
no protection from ST 3 for children, and 
therefore no, or only limited, herd protec-
tion can be expected in other age groups. 
In an analysis of IPD cases among chil-
dren in the United Kingdom [20], the se-
rotype-specific efficacy of PCV13 against 
ST 3 was by far the lowest; it was the only 
serotype with a statistically insignificant 
vaccine efficacy of 26 % (95 % CI, –69 
to 68 %). At the same time, the efficacy 
against the other serotypes in PCV13 (ST 
5 was not calculated because of low case 
numbers) was 82 % (95 % CI, 68–89 %).
It is difficult to assess whether vaccina-
tion of adults with PCV13 or PPSV23 can 
provide protection from illness caused by 
ST 3 because the number of ST 3 cases 
is too low in published studies with clini-
cal endpoints or because information on 
the serotype is missing (see Sect. 6.2). In 
an evaluation of British IPD surveillance 
data according to the Broome method, 
the efficacy of PPSV23 against IPD caused 
by ST 3 (along with the much rarer ST 1) 
in older adults was significantly lower 
than for the other PPSV23 serotypes in-
vestigated [21].
The only randomised controlled tri-
al (RCT) on the efficacy of PCV13 
against clinical endpoints in older adults 
(CAPITA study [22]) showed statistically 
non-significant efficacy of 56 % (95 % CI, 
–6 to 82 %) against PP caused by ST 3 [23]. 
The efficacy against PP by all 13 vaccine 
serotypes was 46 % (95 % CI, 23–62 %). 
These findings align with the assumption 
that PCV13 has an efficacy against ST 3 
comparable with that against the other 12 
serotypes, as well as with the assumption 
that it is significantly less effective against 
ST 3 – as in children – than against the 
other serotypes.
A biological explanation could be that 
the chemical bonding of the capsule poly-
saccharides in S. pneumoniae serotype 3 
(and the epidemiologically insignificant 
ST 37) to the cell wall is weaker than that 
of all other serotypes. That trait allows ST 
3 to separate its capsule polysaccharides 
more easily and thus neutralise circulat-
Fig. 2 8 Relative distribution of serotypes contained in the different pneumococcal conjugate vaccines of the IPD cases recorded in PneumoWeb, by age 
group and year of disease
PCV7 = serotypes contained in the 7-valent pneumococcal conjugate vaccine, PCV10 = serotypes additionally contained in the 10-valent pneumococcal 
conjugate vaccine, PCV13 = serotypes additionally contained in the 13-valent pneumococcal conjugate vaccine
Since 2012, fewer than 20 isolates have been available for serotyping in the age group 5 – 15 years due to very low incidence. Thus the percentages shown 
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ing serum antibodies against ST 3, thereby 
preventing opsonisation which is neces-
sary for phagocytosis of the encapsulated 
pneumococci [24]. Immunogenicity stud-
ies in adults have also shown significant-
ly weaker immune response to ST 3 than 
to other serotypes for both PCV13 and 
PPSV23 [25–28]. In modelling the epide-
miological effects of the vaccination (see 
Sect. 6.5), the base case rested on the as-
sumption that both PPSV23 and PCV13 
are only half as effective against ST 3 as 
against the other serotypes contained in 
the respective vaccine. One sensitivity 
analysis in favour of PCV13 tested the im-
plications of the assumption that PCV13 
is as effective against ST 3 as against the 
vaccine serotypes, yet PPSV23 is only half 
as effective.
5. Approach for evaluating the cur-
rent vaccination recommendation
STIKO took the expansion of the mar-
ket authorisation of PCV13 to include 
all age groups, along with finalisation of 
a major RCT on the efficacy of PCV13 in 
older adults (CAPITA study, see below), 
as an occasion to re-examine its current 
recommendation on the standard vacci-
nation of adults aged ≥60 years (“senior 
vaccination”). This re-examination fo-
cused on:
a) Whether older adults should receive 
one particular vaccine (PPSV23 or 
PCV13) or both sequentially, in con-
sideration of the changes in serotype 
distribution since introduction of uni-
versal infant vaccination
b) At what age the vaccination should be 
administered
c) Whether follow-up vaccinations are 
beneficial
The aim of the vaccination was defined as a 
reduction in the number of invasive pneu-
mococcal diseases and pneumococcal 
pneumonia cases and their consequenc-
es, such as hospitalisation, disability, and 
death, among older adults in Germany.
The following approach was taken to 
answer the three issues above:
1. Exploratory literature research on the 
disease burden of pneumococcal dis-
eases among older people in Germa-
ny, in consideration of hospital diag-
nosis statistics
2. Systematic literature research on the 
efficacy of PPSV23 and PCV13 in old-
er adults against clinical endpoints
3. Systematic literature research on the 
reactogenicity and safety of a one-
time vaccination with PPSV23 or 
PCV13
4. Systematic literature research on the 
immunogenicity, reactogenicity, and 
safety of follow-up vaccinations with 
PPSV23
5. Comparison of the anticipated epide-
miological and health economic ef-
fects of different vaccination strategies 
(vaccine and age at vaccination) using 
transmission modelling and a health 
economic evaluation 
Fig. 4 8 IPD cases in people aged ≥60 years, caused by the 6 serotypes (1, 3, 5, 6A, 7F, 19A) included in 






















Fig. 3 8 Serotype distribution of the IPD cases recorded on PneumoWeb in seniors 60 years and over, 
absolute case numbers
ST3 = serotype 3, non-VT = serotypes not contained in any vaccine 
Seasonal variations of case numbers may reflect real differences in incidence, but may also result from 
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Members of RKI’s Immunisation Unit 
carried out points 1–4. Work package 5 
was set out for public tender and award-
ed to the Center for Health Economics 
Research (CHERH) of the University of 
Hannover. Specifics of the approaches to 
each task were determined in consultation 
with STIKO’s pneumococci workgroup.
The findings of the studies identified 
for points 2 and 3 were summarised in 
meta-analyses based on random effects 
models, using Review Manager 5.2 soft-
ware [29]. The quality of the evidence 
was assessed in line with the methods of 
the Grading of Recommendations As-
sessment, Development and Evaluation 
(GRADE) Working Group [30]. Accord-
ing to GRADE, evidence quality is a meas-
ure of trust in the accuracy of the effect 
estimate. The quality assessment is judged 
separately for each investigated endpoint 
in four levels (high – moderate – low – 
very low). Results of RCTs are ranked 
a priori as “high” quality in GRADE; re-
sults of observational studies are ranked as 
“low” because of the inherently higher risk 
of bias of this study type. Based on certain 
criteria defined in the GRADE method, 
the evidence is examined to determine if 
it justifies a downgrade or upgrade of the 
quality level.
6. Methods and findings regarding 
the various aspects
6.1 Burden of pneumococcal 
diseases among older adults in 
Germany 
It is difficult to estimate the incidence of 
pneumococcal pneumonia (PP) because 
a microbiological diagnosis is confirmed 
in only a fraction of community-acquired 
pneumonia (CAP) patients. One reason 
for this is that in many cases the patient 
receives a calculated antibiotic therapy 
without any effort to establish the patho-
gen; that is the rule in CAP cases treat-
ed on an outpatient basis. Another reason 
is that the viability of pneumococci out-
side the human body is limited. This re-
duces the sensitivity of microbiological 
cultures from blood or sputum samples 
under routine conditions, often with long 
transport times to the laboratory. Micro-
biological cultures are also usually nega-
tive in patients who have begun antibiotic 
treatment. The widespread urine antigen 
test BinaxNOW® S. pneumoniae (Alere 
GmbH, Cologne, Germany) has a sensi-
tivity of only 63–82 %, with a specificity 
of 78–100 % [31], depending on the study.
An exploratory literature search in 
MEDLINE, and a survey of experts in the 
STIKO pneumococci workgroup, failed to 
produce any studies that provided a direct 
estimate of the incidence of PP in Germa-
ny. It can be assumed that the vast major-
ity of PP cases are community-acquired 
[4]. For that reason, we estimated the in-
cidence of PP by multiplying the incidence 
of all CAP by the percentage of CAP cases 
caused by pneumococci as determined in 
other studies.
The CAPNETZ study [8, 32] is the larg-
est prospective study on the microbiologi-
Table 1 Case numbers extracted from hospital diagnosis statistics for Germany, by age, mean values of the years 2010–2013
ICD10 code Cases, 















589 1,446 1,253 58 255 235
G00.1 -Pneumococcal 
meningitis
184 207 160 12 25.5 24
Sum IPD 772 1,653 1,413 70 280 259
Incidence IPD 1.7/100,000 7.6/100,000 8.4/100,000 0.2/100,000 1.3/100,000 1.5/100,000
Pneumonia
J13 – 
Pneumonia caused by 
S. pneumoniae
710 1,703 1,486 33 205 191
J15.9 – Bacterial pneumo-
nia, unspecified
1,762 8,255 7,683 – – –
J18 – Pneumonia, pathogen 
unspecified
35,068 159,775 148,607 – – –
J12-J18 total 
(all codes for pneumonia) 
44,293 192,138 178,022 – – –
Estimated case numbers or 
deaths due to pneumococ-
cal pneumonia*
8,859 38,428 35,604 420 5,162 4,984
Incidence Mortality
Estimated incidence or mor-
tality due to pneumococcal 
pneumonia*
20/100,000 178/100,000 213/100,000 1/100,000 24/100,000 30/100,000
* Assumptions: 20 % of the cases coded as J12-J18 are caused by pneumococci; the lethality of pneumococcal pneumonia equals the ratio (J13 deaths)/(J13 cases)*100
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cal aetiology of CAP cases in adult patients 
in Germany. From 2002 to 2009, a total 
of 7,800 patients with CAP were includ-
ed in the study, of whom about two-thirds 
received inpatient treatment. A pathogen 
was identified in 24.5 % of the 3,720 pa-
tients aged ≥65 years. The most frequently 
identified pathogen was pneumococci, at 
330 cases, comprising 9 % of all CAP cases 
and 33 % of all patients in whom any path-
ogen was identified [8]. The percentage of 
cases caused by pneumococci among cas-
es with no detected pathogen is difficult 
to estimate.
Two recent review articles summa-
rised the findings of studies on the CAP 
pathogen spectrum in various European 
countries [33, 34]. The percentage of PP 
among all CAP cases in the included stud-
ies ranged from 0–67 % [33] and 12–85 % 
[34]. The causes of this gaping difference 
are more likely differences in the diagnos-
tic tests conducted, case definitions, and 
patient collectives, rather than real differ-
ences between countries or studies [33]. 
Based on a meta-analysis (random effects 
model) of 77 individual studies, with a to-
tal of 24,410 CAP patients, Rozenbaum et 
al. [33] estimate the percentage of PP as 
19.3 % (no CI is given) of all CAP cases in 
which a pathogen was detected.
A study of adults in Finland aged ≥65 
years [35], which was published after the 
review by Rozenbaum et al., found a high-
er percentage of PP (30 %; 56 of 187 CAP 
cases with pathogen detection), but the 
PP diagnosis was sometimes confirmed 
serologically (antibodies against pneumo-
coccal surface adhesin A or choline-binding 
protein A). The percentage of PP among 
all CAP cases in the placebo arm of the 
CAPITA trial was only 22 % (174 of 787 
CAP cases), although a specially devel-
oped, highly sensitive urine antigen test 
was used to detect PCV13 serotypes. 
There is no information in the publication 
[22] on the number of CAP cases with de-
tection of any pathogen.
. Table 1 shows case numbers from 
the hospital diagnosis statistics for Ger-
many (www.gbe-bund.de). Less than 1 % 
of all pneumonia cases were coded as PP 
(ICD10 code J13); most certainly a sig-
nificant underestimation of the actual 
percentage. Based on the data reported 
by Rozenbaum et al. [33] and from the 
CAPITA study, we estimate that pneu-
mococci caused roughly 20 % of all cas-
es coded with any ICD10 code for pneu-
monia (J12–J18). At the time of our 
analysis, the most recent figures availa-
ble were from 2013. To compensate for 
inter-seasonal fluctuations, we calculated 
the mean value for 2010–2013: 38,428 PP 
cases in people aged ≥60 years. This cor-
responds to an annual population-based 
incidence of 178 cases of pneumococcal 
pneumonia treated on an inpatient ba-
sis per 100,000 people aged ≥60 years. 
The incidence rose slightly from 2010 
(167/100,000) to 2013 (196/100,000). The 
number of cases coded as invasive pneu-
mococcal disease (ICD10 codes A40.3 
and G00.1) was <5 % of the estimated PP 
cases (. Table 1), which very likely re-
sults from underdiagnosis, as discussed 
above.
We estimated the number of deaths 
due to PP by calculating the case fatality 
of PP as a ratio (J13 deaths/J13 cases)*100 
and multiplying it by the estimated total 
number of CAP cases caused by pneu-
mococci. That resulted in a case fatali-
ty of 12 %, equalling 5,162 deaths caused 
by PP per year in people aged ≥60 years. 
Additionally, 280 deaths caused by inva-
sive pneumococcal diseases (ICD10 codes 
A40.3 and G00.1) were recorded, equal-
ling an annual mortality of 25/100,000 as 
a result of pneumococcal diseases in those 
aged ≥60 years.
This statistic includes only those deaths 
that occurred during hospitalisation; the 
actual mortality is likely higher. In the 
CAPNETZ study, the 30-day case fatality 
of PP cases in people aged ≥60 years was 
somewhat lower, at 7.7 % (32 of 418 cases). 
Notably, this number includes outpatient 
PP cases, which are probably less lethal 
than inpatient cases. There is also a selec-
tion bias in CAPNETZ in favour of those 
less severely ill, because only patients ca-
pable of giving consent were included in 
the study (Mathias Pletz, personal mes-
sage, 12. 2. 2015).
6.2 Efficacy of one-time vaccination 
with PPSV23 or PCV13 against clini-
cal endpoints in older people
Authors GF and CR conducted a system-
atic literature search for studies on the ef-
ficacy of pneumococcal vaccines against 
clinical endpoints. A two-stage strategy 
was used to identify relevant studies. First, 
original works published in or before 2011 
were identified using the broad-based 
Cochrane review “Vaccines for Preventing 
Pneumococcal Infection in Adults,” from 
2013 [36], scrutinising the lists of both in-
cluded and excluded studies. Studies pub-
lished after 2011 were then identified using 
a search strategy adapted to the Cochrane 
review in the databases MEDLINE, Em-
base, and the Cochrane Central Register 
of Controlled Trials, on 3 July 2015 (Flow-
chart see . Fig. A1 in the Appendix). An 
updated search on 15 July 2016 yielded no 
additional hits. The systematic literature 
review was conducted in accordance with 
the Preferred Reporting Items for System-
atic Reviews and Meta-analyses (PRISMA) 
statement [37]. 
Study selection was based on PICO 
questions defined by STIKO (. Table 2). 
In addition to RCTs, observational studies 
(cohort and case-control studies, includ-
ing case-case studies using the Broome 
method [56]) were included as long as re-
sults were adjusted for relevant confound-
ers (e. g. age, comorbidities). Risk of bias 
of included studies was assessed using the 
Cochrane Risk of Bias Tool [57] for RCTs 
and the Newcastle–Ottawa Scale [58] for 
observational studies.
No evaluation was conducted on the 
endpoints “all-cause CAP” and “all-cause 
mortality” because the sizes of the indi-
vidual studies were insufficient to deter-
mine or rule out an effect on these end-
points with adequate statistical power. See 
also the discussion in [43] and the calcu-
lations in [59]. 
Direct comparison PPSV23 vs. 
PCV13 
Only one study with a direct compari-
son of the efficacy of PPSV23 and PCV7 
against clinical endpoints in older adults 
was found [60]. In this randomised, 
non-blinded study, chronic obstructive 
pulmonary disease (COPD) patients 
aged ≥40 years (mean, 63.5 years) were 
vaccinated with PPSV23 or PCV7. The 
primary endpoint of the study was im-
munogenicity data. Of the endpoints de-
fined in our PICO questions, only over-
all mortality was reported. Among 80 
participants in each of the two groups 
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monitored over 2 years, 4 participants 
in the PCV7 group and 7 in the PPSV23 
group died (odds ratio [OR] = 0.55; 95 % 
CI, 0.15–1.95). The extremely wide CI, 
which also includes the value 1, does not 
permit a comparative assessment of the 
two vaccines.
PPSV23 
The efficacy of polysaccharide vaccines 
was investigated in numerous RCTs al-
ready summarised in several meta-anal-
yses. At the time of our own literature 
searches, the Cochrane review by Mober-
ley et al. [36] and a review by Huss et al. 
[61] were the most recent ones. Because 
different studies were included or exclud-
ed, the findings of those two reviews are 
contradictory in some points; see also the 
correspondence between the authors [62, 
63]. Problematic about the two reviews 
(and other older reviews) is that they pool 
data from RCTs of adults of various age 
groups, with various polysaccharide vac-
cines (different valencies, different quan-
tities of antigen), inconsistent case defi-
nitions, and of populations with highly 
varying base risk of pneumococcal dis-
eases [59].
For that reason, we conducted our own 
meta-analysis, including only those RCTs 
that meet the criteria set forth in the PICO 
questions (. Table 2)–a total of 4 RCTs. 
In light of the low case numbers in these 
RCTs and the resulting broad CIs of the 
pooled estimates, we also analysed obser-
vational studies (. Table 3).
Evidence from RCTs. . Fig. 5 shows the 
pooled effect estimates of the RCTs as for-
est plots. Using the formula vaccine effica-
cy (VE) = (1-RR)*100, the pooled vaccine 
efficacy of PPSV23 against IPD is 73 %. The 
CI is very wide due to low case numbers 
(95 % CI, 10–92 %). The IPD cases that oc-
curred in the studies by Honkanen et al. 
and Örtqvist et al. were all caused by vac-
cine serotypes. Maruyama et al. provide 
no information on serotype.
After exclusion of two trials with a high 
risk of bias, the pooled vaccine efficacy of 
PPSV23 against pneumococcal pneumonia 
is 64 %, with a moderately wide CI (95 % 
CI, 35–80 %). Because many cases were di-
agnosed using a urine antigen test, there 
are no data on VE against PP caused by 
vaccine serotypes.
In modelling the various vaccination 
strategies, the VE estimates were inter-
preted as efficacy against IPD or PP caused 
by vaccine serotypes, thus providing a con-
servative assessment of PPSV23.
The meta-analysis for the endpoint 
IPD showed no heterogeneity. Regard-
ing PP, the meta-analysis of all 4 RCTs 
showed considerable heterogeneity 
(I2 = 78 %), which disappeared after ex-
clusion of the 2 RCTs with a high risk of 
bias (I2 = 0 %).
Considerations for inclusion and exclu-
sion of individual RCTs. 1. The results 
of the previously published meta-analy-
ses by Moberley et al. [36] and Huss et al. 
[61] were greatly influenced by the trials 
by Honkanen et al. [41] and Örtqvist et 
al. [40]. We included these two trials for 
the endpoint IPD, but not for the endpoint 
PP because in a large number of cases in 
both studies, the PP diagnosis was based 
on detection of pneumolysin IgG in serum 
[54] or in circulating immune complexes 
in serum [55], using poorly validated in-
house ELISAs. Serum samples from both 
studies were tested at the same laboratory 
in Finland where the in-house ELISAs had 
also been developed. It later became evi-
dent that their specificity was insufficient 
for vaccination efficacy studies.
(a) In the original publication by Jalo-
nen et al. [54], pneumolysin IgG was 
measured in paired serum samples 
of 159 patients (range, 16–95 years 
old; mean, 63 years) with radiologi-
cally confirmed pneumonia. Paired 
serum samples of 27 patients with 
bacteraemia caused by other patho-
gens, and one-time serum samples 
from 29 healthy blood donors (mean 
age, 50 years) served as controls. A 
“positive” result was defined as an an-
tibody concentration exceeding the 
99th percentile of healthy controls in 
at least one of the paired serum sam-
ples, or a ≥ 2-fold titre increase. For an 
ELISA, this cut-off is unusually low (a 
4-fold or greater increase is common) 
because a 2-fold increase can often be 
observed even in repeated measure-
ments of the same serum sample, as a 
result of measurement inaccuracies.
The sensitivity of the test is reported 
Table 2 Inclusion criteria for the systematic literature review (PICO questions)
Population  5 Persons 60 years and over, healthy or with age-typical underlying diseases
 5 Countries/populations with living conditions comparable to those in Germany
Intervention  5 Vaccination with PPSV23
 5 Vaccination with PCV13  
If no studies with PCV13 available: vaccination with PCV7
Comparator intervention  5 No vaccination or placebo 
or
 5 Direct comparison PPSV23 vs. PCV13 (or PCV7)
Endpoints  5 Invasive pneumococcal disease (IPD)  
If data are available: By vaccine serotypes (VT-IPD)
 5 CAP caused by pneumococci (PP), inpatient treatment  
If data are available: By vaccine serotypes (VT-PP)
CRITICAL
 5 CAP caused by pneumococci, outpatient treatment  
If data are available: Limited to vaccine serotypes
 5 All-aetiology CAP
 5 All-cause mortality
IMPORTANT
CAP community-acquired pneumonia
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Table 3 Studies included for the efficacy/effectiveness of PPSV23
Publication Study 
type













RCT Spain COPD patients, 
aged 61–73 years 
298/298 2.7 years Spanish Pneumology Soci-





RCT Japan Residents of retire-
ment homes, 
aged 55–105 years
502/504 2.3 years Japanese Ministry of Educa-





RCT Sweden Former CAP 
patients, 
aged 50–85 years 






(RCT)b Finland Resident populati-
on, aged ≥65 

























(81 % 5–8 years)










up to 5 years Spanish Health Ministry Low Y/Y
Tsai 2015 [45] Cohort 
study
Taiwan Resident popu-
lation, aged ≥75 
years 











(87 % 2–5 years)




CaCo Spain IPD cases ≥65 y + 
matched controls 
149/447 2–3 years Catalonian Health Authority Low Y/Nd
Leventer-Ro-
berts 2015 [48]
CaCo Israel IPD cases ≥65 y + 
matched controls
212/848 up to 5 years Pfizer Low Y/Nd
Vila-Corcoles 
2009 [49]
CaCo Spain IPD and PP cases 
≥50 y (74 % ≥65 









IPD cases ≥65 y 564/551 e up to 5 years Health Protection Agency Low Y/Nd
Gutiérrez 2014 
[50]
Broome Spain IPD cases ≥60 y 588/211 e up to 5 years no information Low Y/Nd
Rudnick 2013 
[51]
Broome Canada IPD cases ≥65 y 1,138/240 e up to 5 years Canadian Institutes for 
Health Research, CDC USA, 
Ontario Thoracic Society, 















CAP cases ≥65 y 279/2,409 f No information No financing High N/Y
CaCo case control study, PY person years follow-up, Y yes, N no, PP pneumococcal pneumonia
aExcluded for endpoint PP because a large number of the reported PP cases were diagnosed using inadequately validated tests for pneumolysin antibodies [54, 55] 
(see comments in the text), bPseudo randomization by birth year (even/uneven), cEndpoint PP not reported, dOnly IPD cases were included in the study, eIPD cases caused by 
vaccine serotypes/IPD cases caused by non-vaccine serotypes, fCAP cases caused by pneumococci/CAP cases without detection of pneumococci
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as 82 %. The publication provides no 
specificity estimate. In general, it is 
difficult to determine the specifici-
ty because there is no “gold standard” 
test to reliably distinguish PP cases 
from pneumonia cases by other pa-
thogens. 
(b) In the original work by Leinonen 
et al. [55] on measuring pneumoly-
sin antibodies in circulating immune 
complexes (ply-IC), 2 to 3 consecu-
tive serum samples from 129 patients 
(range, 15–93 years old; mean age, 
61 years) with radiologically con-
firmed pneumonia were tested, along 
with one-time serum samples from 
109 healthy children and adolescents 
(range, 6 months to 18 years old) and 
11 young adults (range, 20–30 years 
old) as controls. The sensitivity of this 
method is reported as 97.8 %, with a 
specificity of 83.4 %. Doubts regarding 
the validity of this calculation owe to 
the fact that the direct measurement 
of pneumolysin IgG in serum [54] de-
scribed above and even the ply-IC test 
itself were used as part of the defini-
tion of a “real” case of PP, and to the 
considerable age difference between 
cases and controls.
(c) In a later study by Scott et al., co-au-
thored by Leinonen [64], serum sam-
ples from 129 adolescent or adult PP 
patients in Kenya (mean age, 32 years; 
50 % HIV-positive) were examined 
using the ply-IC ELISA. PP was di-
agnosed by cultivating pneumococ-
ci from blood cultures or lung aspi-
rate, or through urine antigen testing. 
Ninety-seven patients (mean age, 35 
years; 31 % HIV-positive) with other 
diagnoses and from the same hospital 
served as controls. 
Up to 3 serum samples were taken 
from the cases (about 6, 11, and 33 
days after disease onset), but only one 
sample was taken from each control. 
Only the highest score from each pa-
tient was used in the calculations, cre-
ating a bias in favour of higher values 
in patients. The sensitivity and spec-
ificity of the ply-IC test were calcu-
lated for various cut-off values. At a 
specificity of 95 % (90 %), sensitivity 
was only 22 % (30 %). In contrast to 
the original publication by Leinon-
en et al. [55], pneumolysin produced 
from genetically altered Bacillus sub-
tilis and Escherichia coli was used as 
the antigen in this study, instead of 
pneumolysin from S. pneumoniae cul-
tures. Both antigens produced broad-
ly consistent results. Of note, Jalonen 
et al. [65] had already shown that 
the ELISA with pneumolysin from S. 
pneumoniae and B. subtilis as the an-
tigen delivers comparable results, and 
it can therefore be assumed that these 
three different methods of pneumo-
lysin production lack any noteworthy 
impact on the ELISA results. 
The authors concluded that measure-
ment of pneumolysin antibodies in cir-
culating immune complexes was not a 
clinically viable test for diagnosing PP 
in their study population because of 
insufficient sensitivity and specificity. 
Furthermore, the test was able to ex-
ceed the sensitivity of blood cultures 
as a diagnostic method only at the ex-
pense of a loss of specificity so great 
that it renders the test useless for vac-
cine efficacy studies [64].
(d) Musher et al. [66] attempted an ex-
ternal validation of the ply-IC meth-
od in the United States. Serum sam-
ples were examined from 16 patients 
with bacteraemic pneumonia, 15 with 
non-bacteraemic pneumonia, 16 with 
pneumococcal colonisation with no 
signs of pneumonia or other acute 
bacterial infection, 16 stable COPD 
patients, and 40 healthy control sub-
jects. The authors followed the lab-
oratory protocol of Leinonen et al. 
[55], using pneumolysin from E. coli 
as the antigen. They found pneumoly-
sin antibodies in circulating immune 
complexes in 60 % of the patients 
with non-bacteraemic PP, 63 % of the 
healthy patients with pneumococcal 
colonisation, 44 % of the stable COPD 
patients, and 23 % of the healthy con-
trols (aged 50–64 years). In bacterae-
mic patients antibody concentrations 
in the acute phase were lower than, 
and the reconvalescence phase similar 
to those in non-bacteraemic pneumo-
coccal pneumonia patients and sub-
jects with pneumococcal colonisation.
The authors conclude that the ply-IC 
test does not allow a distinction be-
tween pneumococcal disease and col-
onisation, and is therefore unsuita-
ble as a method for estimating disease 
burden caused by pneumococci or di-
agnosing pneumococcal pneumonia 
in vaccine efficacy studies [66].
2. After completion of our meta-analysis, 
two further meta-analyses of the efficacy 
of PPSV23 in older adults were published 
in 2016 [67, 68].
(a) The meta-analysis by Schiffner-Ro-
he [67] was commissioned by Pfizer 
and all authors were employees of the 
company or a consulting firm work-
ing for it. Because Pfizer is the man-
ufacturer of the competing product 
PCV13, the authors have a strong 
conflict of interest. 
The authors only considered RCTs. 
They argue that the RCT by Maruy-
ama et al. [39] should not be con-
sidered. They state that the study 
population was not representative of 
the STIKO recommendation’s target 
group because it consisted of retire-
ment home residents, and because 
the study was conducted in Japan, 
not Europe. However, following this 
argument, the RCT by Örtqvist et al. 
[40], which Schiffner-Rohe includ-
ed, should also have been exclud-
ed because all study participants had 
been treated for pneumonia as inpa-
tients and were later vaccinated with 
PPSV23 or placebo. This population 
is also not representative of the target 
group of the STIKO recommendation.
(b) Kraicer-Melamed et al. [68] meta-an-
alysed the efficacy of PPSV23 against 
IPD, all-cause CAP, and PP in RCTs 
and observational studies. They used 
“living in retirement homes” as an 
exclusion criterion for the literature 
search, without further justification. 
Thereby they excluded the Maruy-
ama et al. RCT but included the RCTs 
by Örtqvist et al. and Honkanen et 
al. [41]. Nevertheless, the authors 
concluded that the available data in-
dicated efficacy of PPSV23 against 
IPD and did not exclude efficacy of 
PPSV23 against all-cause CAP.
The participants in the RCT by Maruy-
ama et al. were in fact older, and proba-
bly had more comorbidities than the av-
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 12 · 20161634
Tätigkeitsberichte
erage person aged ≥60 years in Germany. 
It is not clear whether that had any im-
pact on the observed vaccine efficacy. In 
STIKO’s opinion there is no plausible bi-
ological reason why PPSV23 should be 
more effective in this study population 
than in healthier people or the younger 
of older adults. Thus, the efficacy achiev-
able with PPSV23 in the target group of 
the STIKO recommendation is more like-
ly to be underestimated than overestimat-
ed through inclusion of the Maruyama 
study. The same applies to the RCT by 
Örtqvist et al., which we included in our 
meta-analysis for the endpoint IPD. Its ex-
clusion for the endpoint PP was not due to 
any questionable representativeness of the 
study population, but rather, as explained 
above, because of its use of the pneumoly-
sin antibody test with doubtful specificity 
for the diagnosis of PP. For the same rea-
son, we did not consider the Honkanen et 
al. study [41] for the endpoint PP in our 
meta-analysis.
Evidence from observational studies. 
One essential problem of observation-
al studies is that the respective groups of 
vaccinated and unvaccinated people fre-
quently differ with regard to underlying 
diseases and other health-related factors 
(e. g. lifestyle). Correspondingly, the basic 
risk of pneumococcal disease can be dif-
ferent in the two groups, even without vac-
cination. That can lead to a distortion of 
the observed relative risks (i. e. confound-
ing). For that reason, we included only 
studies in which important confounders 
(at least age and comorbidities) were re-
corded and taken into account in an ad-
justed statistical analysis.
Three registry-based cohort studies 
[43, 44, 46], 3 matched case-control stud-
ies [47–49], and 4 “case-case studies” using 
the Broome method [21, 50–52] fulfilled 
this condition. Efficacy against PP was 
also investigated in a study with a simi-
lar case-case design, in which pneumonia 
cases caused by other pathogens or with 
no identified pathogen were used as the 
control group [53]. A large registry-based 
cohort study from Sweden [69] was ex-
cluded because it did not take confound-
ers into account. Not all publications re-
ported findings on all endpoints of interest 
to us.
We used the adjusted odds ratios 
(OR) for the meta-analyses (. Fig. 6). In 
the cohort studies (. Fig. 6a), the pooled 
point estimates of the vaccine effectiveness 
against IPD by any serotype was 45 %, and 
48 % against PP. This is lower than the cor-
responding figures in the RCTs, though 
the CIs overlap widely. The pooled vac-
cine effectiveness against IPD (by any 
serotype) in the case-control studies 
(. Fig. 6b) was 59 %; this figure falls be-
tween the results of the RCTs and the co-
hort studies. Effectiveness was lower in 
the most recent study, conducted by Lev-
enter-Roberts et al. [48]. That may be be-
cause the percentage of IPD cases caused 
by serotypes contained in PPSV23 had al-
Fig. 5 8 Efficacy of PPSV23 against invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP) caused by any serotype, results of RCTs
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Fig. 6 9 Effectiveness of PPSV23 against invasive pneumococcal disease (IPD) and pneumococcal pneumonia (PP), results of observational studies.
a Registry-based cohort studies. The person years of the follow-up are shown as Total. The adjusted odds ratios are shown. The data for the Ochoa-Gondar et 
al. study refer to people who have been vaccinated with PPSV23 within the past five years compared to those who are unvaccinated. b Case control studies. 
c Case-case studies. We calculated the odds ratio for the Andrews et al. study based on the data in Table 3 of the publication for the combined group of 
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ready dropped because of infant vaccina-
tion with PCV7 when the study was con-
ducted in 2008–2010. Correspondingly, 
the effectiveness against IPD caused by 
vaccine serotypes (VT-IPD) in the old-
er case-control studies was only slight-
ly higher than that against IPD caused 
by any serotype, because the percentage 
of non-PPSV23 serotypes was low at the 
time these studies were conducted. The 
pooled effectiveness against VT-IPD in 
the case-case studies using the Broome 
method (. Fig. 6c) was lower, at 39 %. 
The reason for this is not apparent.
The pooled vaccine effectiveness 
against pneumococcal pneumonia caused 
by any serotype was similar across all study 
types: 48 % in cohort studies, 48 % in one 
case-control study, and 37 % in one case-
case study, with broadly overlapping CIs. 
Because many of the cases were diagnosed 
using urine antigen test, there is no sepa-
rate information on the efficacy against PP 
caused by vaccine serotypes.
PCV13 
The efficacy of PCV13 against clinical 
endpoints in people aged ≥65 years was 
investigated in a large placebo-controlled 
RCT (CAPITA trial) in the Netherlands, 
where there is, to date, no general recom-
mendation of pneumococcal vaccination 
for older adults. The results were reported 
in March 2015 in a peer-reviewed publi-
cation [22]. Additional information on the 
study design can be found in [70].
The study participants were recruit-
ed between September 2008 and January 
2010 among residents of the Netherlands 
aged ≥65 years (mean, 72.8 years). Exclu-
sion criteria included immunodeficiency, 
immunosuppression, earlier vaccination 
against pneumococci, or residence in a 
retirement home [70]. Approximately 
42,000 participants were vaccinated with 
PCV13 and around 42,000 with placebo, 
and followed-up for a mean of 4 years. In 
addition to the usual methods for diag-
nosing PP, a specially developed urine an-
tigen test was used. This assay selective-
ly detects antigens of the pneumococcal 
serotypes contained in PCV13 [71]. That 
allowed cases caused by vaccine serotypes 
(VT-PP) to be distinguished from those 
caused by non-vaccine serotypes, even in 
non-invasive pneumococcal pneumonia.
In the per-protocol study population, 
7 cases of VT-IPD occurred in the vacci-
nated group and 28 in the placebo group, 
equalling a vaccine efficacy of 75 % (95 % 
CI, 41–91 %) against VT-IPD. Thirty-three 
cases of non-invasive VT-PP occurred in 
the vaccinated group and 60 in the placebo 
group, equalling a vaccine efficacy of 45 % 
(95.2 % CI, 14–65 %) against non-invasive 
VT-PP. The efficacy of PCV13 against IPD 
caused by any serotype was 52 % (95 % CI, 
22–71 %); against non-invasive PP by any 
serotype it was 24 % (95 % CI, –6 to 46 %).
Case patients who were immunocom-
petent at the time of vaccination, but who 
later developed immunodeficiency, were 
excluded from the per-protocol popu-
lation. These individuals were included 
in the “modified intention-to-treat analy-
sis”. This analysis, which reflects the real 
life situation better than the per-proto-
col analysis, showed a vaccine efficacy of 
76 % (95 % CI, 47–90 %) against VT-IPD 
and 41 % (95.2 % CI, 13–61 %) against 
non-invasive VT-PP. The vaccine efficacy 
against IPD caused by any serotype was 
49 % (95 % CI, 21–67 %); against non-in-
vasive PP caused by any serotype it was 
17 % (95.2 % CI, –10 to 38 %) see . Fig. 7.
The group of excluded participants, 
i. e. those who developed immunodefi-
ciency in the period between vaccination 
and disease, exhibited no statistically sig-
nificant vaccine efficacy of PCV13. This 
may have been due to the small number 
of cases (4 cases of VT-IPD, 17 cases of 
non-invasive VT-PP). Arithmetically 
vaccine efficacy against non-invasive VT-
PP in this group was 30 % (95 % CI, –105 
to 78 %) [23].
The CAPITA trial demonstrated a sta-
tistically significant vaccine efficacy of 
PCV13 against IPD (VT and any sero-
type) and against non-invasive PP by vac-
cine serotypes. However, no significant 
efficacy was observed against non-inva-
sive PP by any serotype. This holds true 
for both the per-protocol and the modi-
fied-intention-to-treat analysis.
Quality of evidence based on 
GRADE criteria
Regarding PPSV23, we ranked the quality 
of the evidence for both endpoints (IPD, 
PP) at the second-highest level, “mod-
erate”. RCTs are primarily classified as 
high-quality evidence in GRADE. The 
downgrade owed to the wide CIs of the 
efficacy against IPD and a study popula-
tion that deviates from the PICO ques-
tion (indirectness) for the endpoint PP 
(see GRADE profile . Table A1 in the 
Appendix). That results in a degree of un-
certainty regarding the actual level of the 
efficacy of PPSV23.
Regarding PCV13, we ranked the 
quality of evidence as “high” for the end-
point VT-IPD, and as “moderate” for the 
endpoint VT-PP, because of the wide CI 
(see GRADE profile . Table A2 in the 
Appendix). We did not assess the quali-
ty of evidence for the endpoints IPD and 
PP caused by any serotype because the 
observed efficacies were largely deter-
mined by the local serotype mix at the 
time of the study. Because infants in the 
Netherlands were vaccinated with PCV7 
or PCV10 at the time of the CAPITA 
study, the serotype mix is not compara-
ble to the current situation in Germany, 
where herd protection by universal in-
fant vaccination with PCV13 since 2010 
has led to a significant drop in PCV13 
serotypes (except ST 3) in all age groups.
Comparative assessment of efficacy 
data for PPSV23 and PCV13 
The point estimates from RCTs for efficacy 
against IPD caused by serotypes contained 
in the respective vaccine are nearly identi-
cal: 73 % for PPSV23 and 76 % for PCV13 
(modified intention-to-treat analysis). The 
efficacy of PPSV23 against PP caused by 
any serotype was significantly higher (64 % 
in RCTs and 48 % in cohort studies) than 
that of PCV13 (17 %), and similar to the 
efficacy of PCV13 against vaccine-type PP 
(41 %). However, the CIs are so wide that 
a comparative assessment of the two vac-
cines is scarcely possible. Thus, it cannot 
be ruled out with certainty that one of the 
two vaccines may have a greater or lower 
efficacy to a relevant degree.
With regard to the endpoint PP, the 
data on vaccine efficacy from RCTs are 
based on only one RCT with PCV13 
(CAPITA study) and only 2 RCTs with 
PPSV23. Furthermore, the pooled vac-
cine efficacy of PPSV23 is largely deter-
mined by the Maruyama et al. RCT. None 
of the 3 RCTs investigated a study pop-
ulation completely representative of the 
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STIKO recommendation target group. On 
average, the participants in the trials by 
Maruyama et al. and Alfageme et al. were 
older and/or (probably) had more comor-
bidities, which may lead to underestima-
tion of the vaccine efficacy achievable by 
PPSV23 among older adults in Germany. 
Conversely, the efficacy of PCV13 among 
older adults in Germany is probably low-
er than that recorded in the CAPITA tri-
al because CAPITA only included people 
without immunodeficiency or immuno-
suppression.
It is often claimed that the protection 
offered by the pure (non-conjugate) poly-
saccharide vaccine against PP has not 
been proved (e. g. [22, 61]). However, the 
current Cochrane review from 2013 [36] 
shows a pooled efficacy of 28 % (95 % CI, 
7–44 %) against all-cause pneumonia. This 
means that efficacy against PP must be 
higher, because only a fraction of all CAP 
cases is caused by pneumococci. Studies 
of very different populations (i. e. young 
and old, developed and developing coun-
tries) were included in that meta-analy-
sis, leading to a large heterogeneity of the 
results. Polysaccharide vaccines demon-
strated high efficacy against PP in sever-
al classic RCTs conducted in the 1970s 
among young South African goldminers, 
who had a very high risk of pneumococ-
cal pneumonia. In this population, high-
ly significant vaccine efficacies of 76–92 % 
against VT-PP have been observed for 
various experimental 6-, 12-, and 13-va-
lent PPSVs [72, 73]. Even though these 
findings cannot be applied quantitatively 
to people aged ≥60 years, or to the cur-
rent PPSV23 vaccine, they do impressive-
ly demonstrate the proof of principle that 
pure polysaccharide vaccines can provide 
protection from PP.
From a pathophysiological perspective, 
it appears implausible that protection from 
non-bacteraemic pneumonia should sole-
ly depend on prevention of pneumococ-
cal colonisation of the upper respiratory 
tract through mucosal antibodies. When 
a colonised person aspirates pneumococ-
ci it leads to a local inflammatory reaction 
with the exudation of plasma (oedema flu-
id) into the alveoli. The emergent plasma 
antibodies and complement components 
cause opsonisation of the pneumococci in 
the alveoli and, thus, induce their phago-
cytosis and killing [74]. Thereby, plasma 
antibodies also contribute to preventing 
clinical manifestation of pneumonia. The 
result of the Maruyama et al. [39] RCT, in 
which an efficacy of 62 % (95 % CI, 30–
79 %) of PPSV23 against PP by any sero-
type was observed in retirement home res-
idents, underscores this view.
With regard to the population-based 
impact achievable by the two vaccines, 
it must be noted that the serotypes con-
tained in PCV13 have regressed consid-
erably since the use of PCV7 and PCV13 
for infant vaccination. In the 2015–’16 
season they caused only 30 % of the IPD 
cases in people aged ≥60 years in Ger-
many. In contrast, serotypes contained 
in PPSV23 caused 70 % of the IPD cases 
in this age group (. Fig. 3). The conse-
quence is that vaccination with PPSV23 
can prevent more IPD cases at the popula-
tion level than PCV13, even if the efficacy 
of PPSV23 were only half that of PCV13.
No recent data are available on sero-
type distribution in non-invasive PP cas-
es in Germany because, in these cases, of-
ten no pathogens are cultivated (e. g. from 
sputum) and the diagnosis is based on a 
positive BinaxNOW® urine antigen test, 
which does not allow for serotype dif-
ferentiation. Presumably serotype distri-
bution is influenced by herd protection 
through infant vaccination in a similar 
manner as in IPD cases. In Denmark, se-
rotype distribution in PP cases in adults 
was investigated in 2011, 1 year after the 
switch from PCV7 to PCV13 in the infant 
vaccination programme [75]. In PP cas-
es with bacteraemia (i. e. IPD cases), the 
proportion of PCV13 serotypes was 59 % 
(95 % CI, 48–70 %), and that of PPSV23 
serotypes was 87 % (95 % CI, 74–100 %). 
A similar relative distribution, though at 
a lower level, was found among non-bac-
teraemic PP cases (pathogen cultivation 
from sputum, pleural punctate, or bron-
Fig. 7 8 Efficacy of PCV13 against invasive pneumococcal diseases (IPD) and non-invasive pneumococcal pneumonia (ni-PP), CAPITA RCT, modified 
intention-to-treat analysis
This graph was created using the Review Manager software. In some cases, the boundaries of the confidence intervals (CI) deviate slightly (by 0.01 to 0.02) 
from the figures in the publication, where a different statistical procedure was used to calculate the CI, and in some cases a 95.2 % CI was given
Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz 12 · 20161638
Tätigkeitsberichte
chial lavage); 34 % (95 % CI, 25–43 %) of 
which were caused by PCV13 serotypes 
and 57 % (95 % CI, 48–66 %) by PPSV23 
serotypes.
Rodrigo et al. [76] studied the serotype 
distribution among mostly non-bacterae-
mic PP cases in adults (median age, 71 
years) in England. Over 5 years (Septem-
ber 2008 to August 2013) 2,229 in-patients 
with CAP at two major hospitals in Not-
tingham were included. In 653 (29 %) of 
these patients, PP was diagnosed, thereof 
87 (13 %) with bacteraemia. In April 2010, 
approximately half way through the study, 
the infant vaccination programme in Eng-
land switched from PCV7 to PCV13. 
Compared with the study period before 
the switch to PCV13, a reduction in PP 
cases caused by PCV13 of approximate-
ly 40 % occurred thereafter. The greatest 
reduction was in serotypes also contained 
in PCV7 (–88 %); while the six extra se-
rotypes contained in PCV13 dropped by 
30 %. It is not surprising that the six ex-
tra serotypes dropped less, because only 
the first 3 years after the switch to PCV13 
in the infant vaccination programme were 
investigated, and it can take several years 
for herd protection effects to accumulate 
[77].
Duration of vaccine protection 
The duration of protection provided by 
PPSV23 can be roughly estimated through 
an overall assessment of the findings of 
our meta-analyses. The vaccine efficacy of 
PPSV23 observed in the RCTs applies to 
a follow-up period of 2–3 years after vac-
cination. In contrast, a variable – on av-
erage longer – period following vaccina-
tion was investigated in the cohort studies 
because many of the participants had al-
ready been vaccinated several years before 
recruitment. This probably explains why 
the observed vaccine effectiveness in the 
cohort studies was lower.
The effectiveness for PPSV23 of 48 % 
against PP and 62 % against IPD cited for 
the cohort studies by Ochoa-Gondar et al. 
[44] in this report apply to people who had 
been vaccinated in the previous 5 years, 
compared with people never vaccinated 
against pneumococci. People who had 
“ever [been] vaccinated” (i. e. including 
vaccinations >5 years ago) did not have a 
significantly lower illness rate than those 
never vaccinated. That means that no sig-
nificant protection was detectable for the 
period exceeding 5 years after vaccination.
Andrews et al. [21] arrived at similar 
results in their calculation of PPSV23 ef-
fectiveness using the Broome method. 
For people aged 65–74 years, effective-
ness against VT-IPD was 65 % (95 % CI, 
23–84 %) within <2 years after vaccination 
and 62 % (95 % CI, 21–82 %) in the period 
2–5 years after vaccination. More than 5 
years after vaccination, a significantly low-
er, and statistically no longer significant, 
effectiveness of 28 % (95 % CI, –72 to 70 %) 
was found (Table 4 in [21]).
These data suggest that vaccine effi-
cacy after a one-time vaccination with 
PPSV23 declines continuously from a rel-
atively high level shortly after vaccination. 
As soon as 5 years after vaccination a large 
portion of those vaccinated may no longer 
be protected.
Regarding duration of protection after 
vaccination with PCV13 of older adults, the 
CAPITA study [22] provides the only avail-
able data. No significant reduction in vac-
cine efficacy was detected during the 4-year 
follow-up period in this RCT. However, the 
case number in the fourth year was so low 
that an onset of reduction cannot be ruled 
out. Data from children’s vaccination sug-
gest that the duration of protection provid-
ed by a one-time vaccination with PCV13 
is limited [78].
6.3 Reactogenicity and safety of a 
one-time vaccination with PPSV23 
or PCV13
Authors SG and TH identified studies on 
the reactogenicity and safety (“safety as-
pects”) of PPSV23 and PCV13 in old-
er adults by using a systematic literature 
search based on the PICO questions in 
. Table 4. See . Fig. A2 in the Appen-
dix for the search strategy and flow chart.
Three studies (two RCTs and one co-
hort study) on safety aspects were found 
for PPSV23, and two RCTs for PCV13. In-
activated influenza vaccine (IIV) was ad-
ministered at the same time to both the 
intervention and control groups. Data on 
safety aspects from the CAPITA study 
(RCT PCV13 vs. placebo) available in 
the form of a supplementary appendix 
[23] since March 2015 were taken into 
account retroactively. Safety aspects in a 
direct comparison between PPSV23 and 
PCV13 were investigated in three RCTs 
(. Table 5).
. Table 6 lists the results of the stud-
ies on PPSV23 or PCV13. The publication 
by Grilli et al. [79] contained no evaluable 
data. Information on the endpoint “un-
planned medical visits” was found only 
in D’Alessandro et al. [81]. A total of 305 
people (1 % of the study population) had 
an unplanned medical examination, 1.3 % 
in the intervention group and 0.9 % in the 
control group. Four people – all vaccinat-
ed with PPSV23 and IIV – were hospital-
ised because of dyspnoea with malaise, 
long-lasting fever, bronchopneumonia, or 
circulatory collapse, though it is unclear 
whether there was a causal relationship 
with the vaccination.
PPSV23 + inactivated influenza 
vaccine (IIV) vs. IIV alone
The assessment was based on the studies 
by Honkanen et al. [80] and D’Alessan-
dro et al. [81] Unplanned medical visits, 
muscle pain, joint pain, local reactions, 
and/or malaise/fatigue occurred signifi-
cantly more frequently among those vac-
cinated with PPSV23 than in the control 
group. There was no significant difference 
in frequency of fever and headache. The 
GRADE-ing of the best available evidence 
resulted in “very low” to “low” quality of 
the evidence for the investigated end-
points (see GRADE profile . Table A3 
in the Appendix).
PCV13 (+IIV) vs. placebo (+IIV)
In the three evaluated RCTs [23, 82, 83], 
those vaccinated with PCV13 reported 
muscle pain and local pain significantly 
more often (GRADE: “moderate” qual-
ity of evidence). Fever, malaise, head-
ache, muscle and joint pain occurred 
more frequently among those vaccinat-
ed with PCV13, but the differences were 
not (or not in all three studies) significant 
(GRADE: “low” and “moderate” quality of 
evidence, respectively. See GRADE profile 
. Table A4 in the Appendix)
PPSV23 vs. PCV13
In the direct comparison of the two vac-
cines (. Table 7) there was a consistently 
higher percentage of muscle pain among 
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PPSV23 recipients across all evaluated 
studies. Only slight differences were de-
tected for the other investigated safety 
endpoints, without a clear trend in favour 
of either vaccine. Only percentages were 
reported in the three RCTs. It is not pos-
sible to translate these back into absolute 
numbers. For that reason, an assessment 
based on GRADE could not be conducted. 
Summary and assessment of the 
safety aspects
For the most part, more adverse events oc-
curred in the intervention groups than in 
the control groups, regardless of the vac-
cine being PPSV23 or PCV13. The quali-
ty of evidence is in the area of “very low” 
to “moderate”. Frequency of side effects 
must not be compared across studies with 
PPSV23 + IIV and PCV13 + IIV because 
of the different follow-up periods and re-
cording methods.
In the direct comparison of PPSV23 
and PCV13, muscle pain was observed 
more frequently after PPSV23, but the 
difference was significant in only one of 
the three studies. The other investigated 
endpoints appear to occur with similar 
frequency after both vaccines, but there 
are some major differences in the report-
ed frequency of individual endpoints (e. g. 
fever) between studies. The presentation 
of the data in the publications does not al-
low meta-analysis.
Based on the limited data available, no 
important differences in reactogenicity be-
tween PPSV23 and PCV13 could be detect-
ed. However, there are no studies on pos-
sible side effects that occur >14 days after 
vaccination, and the sizes of the identified 
studies are insufficient to detect rare po-
tentially serious side effects.
6.4 Efficacy and reactogenicity of 
repeated vaccination with PPSV23
Approach
To assess this question, authors CR, TH, 
and GF on 26 June 2015 conducted a sys-
tematic literature research based on the 
PICO questions in . Table 8 in the data-
Table 4 Inclusion criteria for the literature research on safety aspects in older adults (PICO questions)
Population  5 Persons 60 years and over, healthy or with age-typical underlying disease (expanded search for adults age ≥50 years, 
depending on data available)
 5 Countries/populations with living conditions comparable to those in Germany
Intervention  5 first vaccination with PPSV23 (no follow-up vaccination)
 5 first vaccination with PCV13 (no follow-up vaccination)
Comparator intervention  5 No vaccination or placebo 
or
 5 Direct comparison PPSV23 vs. PCV13
Endpoints  5 Fever >38°C (>100°F) ≤14 days after vaccination
 5 Unplanned medical visits ≤14 days after vaccination 
 5 Systemic effects: headache, malaise, muscle and/or joint pain
 5 Severe local reactions: pain
Table 5 Studies included on safety aspects of the vaccination with PPSV23 or PCV13 in older adults
Publication Study 
type
Country Study population Intervention Control
Grilli 1997 [79] RCT Italy Retirement home residents, age: 78 years 
(range: 41–94 y)




Honkanen 1996 [80] RCT Finland Resident population, 
age ≥65 years 




D’Alessandro 2004 [81] CS Italy Vaccination of seniors ≥65 years by general 
practitioners 
PPSV23 + IIV 
n = 12,485 
IIV 
n = 16,601 
Frenck 2012 [82] RCT USA Healthy adults 50–59 years; phase 3 study PCV13 + IIV 
n = 551 
Placebo + IIV 
n = 560 
Schwarz 2011 [83] RCT Germany Healthy adults ≥65 years PCV13 + IIV 
n = 576
Placebo + IIV 
n = 575
Bonten 2015 [23] RCT Nether-
lands








Jackson 2013 [85] RCT USA Seniors 60–64 years PPSV23
n = 414
PCV13
n = 417 
Juergens 2014 [86] RCT South 
Africa




CS cohort study, IIV inactivated influenza vaccine, RCT Randomized controlled trial
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bases MEDLINE, Embase, and Cochrane 
Central Register of Controlled Trials. A 
search was also conducted in the reference 
lists of the studies included, as well as the 
registry of clinical trials, Clinicaltrials.gov. 
We followed the PRISMA directives [37] 
in conducting the systematic literature re-
view. A detailed report of our review has 
been accepted for publication in BMC In-
fectious Diseases (Remschmidt et al.).
The literature search resulted in 1,162 
returns, of which only 14 studies [26, 
27, 60, 87–97] met the inclusion crite-
ria (see . Table 9). We excluded studies 
that examined only immunosuppressed 
patients (e. g. HIV-positive patients or 
kidney transplant patients), in which 
a different vaccine formulation (e. g. 
PPSV14) was used, or in which the re-
peat vaccination was administered with-
in 1 year of the initial vaccination. Data 
on clinical endpoints were not reported 
in any of the included studies. Nine stud-
ies reported immunogenicity data, and 
10 reported data on safety and reacto-
genicity. 
Immunogenicity
Immunogenicity data were reported in 9 
studies [26, 27, 88–90, 92, 93, 96, 97]. IgG 
Table 6 Reactogenicity of the vaccination with PPSV23 or PCV13 in older adults
Honkanen 1996 D’Alessandro 2004 Frenck 2012 Schwarz 2011 Bonten 2015 
(CAPITA study)
Follow up 4 days 3 days 14 days 14 days 7 days
I PPSV23 + IIV PPSV23 + IIV PCV13 + IIV PCV13 + IIV PCV13 a
C IIV IIV Placebo + IIV Placebo + IIV Placebo a
Endpoint
Fever ≥38°C 
I 9/4755 (0.2 %) 329/12,485 (2.6 %)b 9/261 (3.4 %) 18/431 (4.2 %) 26/885 (2.9 %)
C 5/4581 (0.1 %) 185/16,601 (1.1 %)b 4/257 (1.6 %) 14/433 (3.2 %) 11/860 (1.3 %)
Unplanned medical visits
I n.i. 163/12,485 (1.3 %) n.i. n.i. n.i.
C n.i. 142/16,601 (0.9 %) n.i. n.i. n.i.
New muscle pain
I n.i. 135/12,485 (1.1 %)c 252/385 (65.5 %) 126/468 (26.9 %) 165/896 (18.4 %)
C n.i. 52/16,601 (0.3 %)c 123/326 (37.7 %) 76/456 (16.7 %) 73/868 (8.4 %)
Any aggravated muscle pain
I n.i. 109/314 (34.7 %) 85/454 (18.7 %) 81/889 (9.1 %)
C n.i. 71/294 (24.1 %) 63/449 (14.0 %) 38/866 (4.4 %)
New joint pain
I n.i. 128/12,485 (1.0 %)c 102/309 (33.0 %) 73/452 (15.7 %) 66/886 (7.4 %)
C n.i. 55/16,601 (0.3 %)c 73/296 (24.7 %) 59/451 (13.0 %) 47/866 (5.4 %)
Any aggravated joint pain
I n.i. 62/292 (21.2 %) 71/452 (15.7 %) 46/884 (5.2 %)
C n.i. 51/284 (18.0 %) 58/447 (13.0 %) 36/865 (4.2 %)
Local pain 
I 441/4,755 (9.3 %)d 902/12,485 (7.2 %) 407/469 (86.8 %) n.i. 330/914 (36.1 %)
C 284/4581 (6.2 %)d 555/16,601 (3.3 %) 119/321 (37.1 %) n.i. 53/863 (6.1 %)
Headache
I n.i. 74/12,485 (0.6 %) 263/399 (65.9 %) 154/472 (32.6 %) 142/892 (15.9 %)
C n.i. 75/16,601 (0.5 %) 216/382 (56.5 %) 139/468 (29.7 %) 130/878 (14.8 %)
Malaise/fatigue
I n.i. 323/12,485 (2.6 %) 226/389 (58.1 %) 178/476 (37.4 %) 168/895 (18.8 %)
C n.i. 222/16,601 (1.3 %) 188/359 (52.4 %) 154/483 (31.9 %) 130/876 (14.8 %)
Significantly different values in bold. 
I intervention arm, C control arm, IIV inactivated influenza vaccine, n. i. no information
aThe majority of subjects in both study arms were also vaccinated against influenza. In the safety population the influenza vaccination was administered at least 7 days 
before or after the PCV13 or placebo vaccination, bFever >37.8°C, cNo distinction between newly occurring pain and aggravation of existing pain, dLocal reactions of all types 
(pain, swelling, redness); pain not reported separately
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levels were measured in 8 studies with dif-
ferent ELISA assays; the consensus ELISA 
recommended by WHO was used in only 
2 studies. Five studies used an opsono-
phagocytic activity (OPA) assay.
We did not pool the data because the 
antibody (AB) levels are not comparable 
across studies (different laboratory assays, 
AB against different serotypes measured, 
different populations, different time inter-
vals between vaccination and blood sam-
pling). To compare the results of AB levels 
across studies, we calculated within each 
individual study the ratio of the AB lev-
el at identical time points after (or before) 
the second and first dose of PPSV23. This 
dimensionless ratio allows comparison of 
the results of the various studies. A ratio 
of >1 means that the AB level was higher 
at the same point in time after the second 
dose than after the first.
In general, the AB levels before the sec-
ond dose (3–10 years after the first dose) 
were higher than in PPSV23-naive individ-
uals before the first dose. At 1 and 2 months 
after vaccination, the ratio was mostly be-
tween 0.7 and 1; i. e. shortly after the second 
dose the rise in AB levels was less marked 
than after the first dose (. Fig. 8). Only two 
studies measured AB levels 1 or 2 years af-
ter vaccination. The ratio for most sero-
types was close to 1 in Dransfield et al. [60]. 
In Musher et al. [27] the ratio was >1 after 2 
years; i. e. AB levels were higher on average 
after the second PPSV23 dose. In all four 
studies in which the AB levels were meas-
ured 5–10 years after the second dose, they 
were consistently higher than, or at least as 
high as, 5–10 years after the first dose (ra-
tio ≥1). 
Musher et al. [27] also examined AB lev-
els after a third dose administered 10 years 
after the second. One month after the third 
dose, the AB levels were somewhat lower 
than 1 month after the second dose, but it 
must be taken into account that the study 
participants were 10 years older at the time 
of the third vaccination.
These results refute a sustained hypo-
responsiveness after follow-up PPSV23 
vaccinations in adults. They concur with 
comparative analyses in older adults (aged 
50–80 years), who exhibited similar quan-
tities of anti-PPS antibody producing plas-
ma cells and memory B cells in peripheral 
blood (measured by ELISPOT without or 
with restimulation) 1 week or 2 years after 
vaccination with PPSV23 or PCV7 [98, 99]. 
The reduced frequency of memory B cells 
in peripheral blood through PPSV23, de-
scribed but mechanistically not yet defined 
by a different workgroup, was mostly limit-
ed to a period of 4 weeks after vaccination. 
After 6 months, the number of peripheral 
memory B cells in the PCV7 and PPSV23 
groups had fallen to a similar level [100].
As T-cell-independent antigens, pneu-
mococcal polysaccharides (PPS) do not 
trigger a stronger immune response after 
repeated immunisation. However, vari-
ous studies have shown that PPS induce 
efficient activation of IgM+ memory B 
cells (IgM+IgD+CD27+) and generation of 
long-lived plasma cells (CD38+CD20low). 
This is accompanied by the generation 
and persistence of IgM and IgG antibod-
ies against PPS [101–108]. IgM+ memo-
ry B cells circulating in the blood are the 
peripheral correlates of the marginal zone 
B cells of the spleen. They develop within 
Table 7 Reactogenicity of the vaccination with PPSV23 or PCV13 in direct comparison
Greenberg 2014 a Jackson 2013 Juergens 2014 b
Follow up 14 days 14 days 14 days
Endpoint
Fever ≥38°C
PPSV23 1.6 % 1.1 % 9.6 %
PCV13 4.2 % 4.0 % 8.3 % 
Unplanned medical visits
PPSV23 n.i. n.i. n.i.
PCV13 n.i. n.i. n.i.
New general muscle pain
PPSV23 51.5 % 57.8 % 25.1 % 
PCV13 46.9 % 56.2 % 24.6 % 
Aggravated muscle pain
PPSV23 32.5 % 37.3 % 16.0 % 
PCV13 22.0 % 32.6 % 13.0 % 
New joint pain
PPSV23 23.8 % 30.1 % 13.0 % 
PCV13 15.5 % 24.4 % 10.7 % 
Aggravated joint pain
PPSV23 21.1 % 21.4 % 10.4 % 
PCV13 14.0 % 24.9 % 9.2 % 
Local pain
PPSV23 0.8 % c 8.6 % 2.1 % c 
PCV13 2.3 % c 1.7 % 3.0 % c 
Headache
PPSV23 46.1 % 54.4 % 30.7 % 
PCV13 49.7 % 54.0 % 30.6 % 
Malaise/fatigue
PPSV23 49.1 % 61.5 % 34.8 % 
PCV13 50.5 % 63.2 % 28.1 % 
Significantly different values in bold; n. i. no information 
aFor the endpoint “severe local reactions”, the percentages refer to a study size of 127 to 180 persons 
in the PPSV23 group and 258 to 374 in the PCV13 group. For all other endpoints the study size was 
127 to 202 persons in the PPSV23 group and 258 to 383 persons in the PCV13 group, b The percent-
ages refer to a study size of 235 to 264 persons in the PPSV23 group and 234 to 271 persons in the PCV13 group. 
No p-values are given in the publication, cSevere local pain
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the first 2 years of life as part of the mar-
ginal zone’s maturation. They are absent 
in asplenic patients [103, 105, 108]. With 
increasing age, the number of IgM+Ig-
D+CD27+ memory B cells in the blood 
drops substantially, as do, to a lesser de-
gree, the numbers of plasma cells and IgM-
IgD-CD27+ switched memory B cells. This 
causes a lower anti-PPS IgM response af-
ter PPSV23 vaccination, while the an-
ti-PPS IgG response (as is the opsonisa-
tion activity of the serum) is preserved by 
stimulation of switched memory B cells 
[109–112]. Although the lower IgM re-
sponse may negatively influence vaccine 
efficacy, these findings, on the whole, in-
dicate that PPSV23 is immunogenic also 
in older adults.
Reactogenicity and safety of 
re-vaccinations 
We identified 10 studies that compared 
the frequency of adverse drug reactions 
(ADRs) after a first and second vaccina-
tion with PPSV23. Five [27, 88–90, 93] 
were prospective studies in which the par-
ticipants recorded ADRs in a diary for 14 
days after vaccination. Four studies [91, 
94, 95, 97] used large databases to iden-
tify unplanned medical visits (i. e. emer-
gency room, hospitalisation) 1–30 days af-
ter the respective vaccination. In one study 
[87] vaccinated people were asked retro-
spectively by telephone about ADRs. As 
these interviews did not take place until 
8 months after the vaccination, there are 
considerable doubts about the accuracy 
of the answers. For that reason, we have 
excluded this study from further analyses. 
Results
Across studies, fever (0–9 % after first 
dose, 0–10 % after second dose) and un-
planned medical visits (0.3–2.2 % in total) 
were reported with similar frequency. For 
other ADRs there were marked differenc-
es across studies; for example, headache 
was reported by 2–61 % of the vaccinees 
after the first dose, and in 13–57 % after 
the second dose.
Depending on the endpoint, 1–3 stud-
ies reported significantly more unplanned 
medical visits, headache, general malaise, 
muscle pain, joint pain, severe local pain, 
and/or limitations in arm movement af-
ter the re-vaccination than after the ini-
tial vaccination. No significant differences 
were found with regard to fever or severe 
ADRs.
In a stratified analysis, two studies [27, 
94] found significant differences in the 
rate of ADRs only if the interval between 
the first and second dose was <5 years. If 
the interval was >5 years [94] or 10 years 
[27], the difference was described as no 
longer statistically significant. In par-
ticipants who received a second dose of 
PPSV23 5–13 years after the initial vacci-
nation, Jackson et al. [89] found no statis-
tically significant dependence of the ADR 
frequency on the interval between the 
vaccinations. However, there was a sig-
nificant correlation of ADR frequency to 
AB levels shortly before the second dose.
Some studies also reported ADRs after 
further (third and fourth) PPSV23 vacci-
nations. No additional increase of ADRs 
could be clearly observed.
In summary, the rate of non-severe 
ADRs was higher after re-vaccination than 
after the initial vaccination. Data indicate 
that an interval of <5 years between the 
first and second vaccine dose is associ-
ated with higher ADR frequency. Addi-
tional vaccinations (third or fourth) do 
not appear to lead to increased ADR fre-
quency.
6.5 Transmission model and health 
economic evaluation 
The epidemiological modelling of pneu-
mococcal diseases (IPD and PP) and 
health economic evaluation of various 
vaccination strategies were conducted 
by the Center for Health Economics Re-
search (CHERH) at the University of Han-
nover. Here, the main assumptions and re-
sults of the modelling are described. The 
full project report (in German) is available 
from the RKI website: www.rki.de/impfen 
> Forschungsprojekte.
Model structure
As mentioned, herd protection through 
childhood vaccination with PCV13 
strongly influences serotype distribu-
tion of pneumococcal diseases in all age 
groups, including the target group of peo-
ple aged ≥60 years. Two circumstances are 
decisive:
1. Children are the main source of pneu-
mococcal infection for older people, 
because children are much more fre-
quently nasopharyngeal carriers of 
Fig. 8 8 Ratios of immunoglobulin G (IgG) concentration 
This figure summarizes the ratios of the geometric mean IgG concentrations (GMC) for all serotypes 
and times after vaccination reported in all 8 included studies. The boxes indicate the 25th and 75th 
percentile of the GMC ratios; the horizontal line within the box is the median ratio. A ratio of >1 means 
that the GMC was higher at the same point in time after the 2nd dose than after the 1st dose
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pneumococci than are older adults 
[113].
2. The pneumococcal conjugate vaccines 
used to vaccinate infants provide se-
lective protection from nasopharyn-
geal colonisation with vaccine sero-
types. Therefore, they influence the 
serotype mix in colonised children 
and, thus, the serotype mix in disease 
cases in all age groups as well. 
To take this phenomenon into account, a 
dynamic transmission model was devel-
oped. Pneumococcal serotypes were di-
vided into five groups: PCV7 serotypes, 
additional serotypes in PCV13 except se-
rotype (ST) 3, ST 3, additional serotypes 
in PPSV23 (minus ST 6A), and non-vac-
cine serotypes. ST 3 is a special case be-
cause vaccination efficacy against this se-
rotype is questionable (see Sect. 4). In the 
base case, it is assumed that PPSV23 and 
PCV13 are half as effective against ST 3 as 
against the other serotypes contained in 
the respective vaccine.
The transmission parameters that de-
termine nasopharyngeal colonisation 
were calibrated based on the effects ob-
served in Germany since introduction of 
universal infant vaccination and – under 
the assumption of stable vaccine uptake in 
infants – used to predict future develop-
ment of case numbers and serotype mix 
in disease cases (IPD, PP) among older 
adults. Data on the varying invasiveness 
of different serotypes were taken into ac-
count [114, 115].
As the next step, the epidemiological 
and health economic effects of the fol-
lowing vaccination strategies were ex-
amined: 
 5 one-time vaccination with PPSV23 
 5 one-time vaccination with PCV13 
 5 sequential vaccination with PCV13 + 
PPSV23 
 5 repeated vaccinations with PPSV23 
after initial vaccination with PPSV23 
 5 repeated vaccinations with PPSV23 
after sequential initial vaccination 
with PCV13 + PPSV23 
In the base case, modelling was based on 
the assumptions listed in . Table 10, 
which were varied in several sensitivity 
analyses.
Assessment of epidemiological 
effects
The model predicts a continued marked 
reduction in the percentage of PCV13 se-
rotypes in pneumococcal disease cases 
among older adults, resulting from herd 
protection through infant vaccination. 
Therefore, in the coming years, the share 
of pneumococcal disease episodes pre-
ventable by vaccination of older adults 
with PCV13 would be limited to <30 % 
of all cases, even with a theoretical vac-
cine efficacy of 100 % and vaccine uptake 
of 100 %.
The main epidemiological and health 
economic results of the model are summa-
rised in . Table 11 and 12. The numbers 
of preventable cases etc. shown apply to 
the remaining lifespan of people reach-
ing the respective vaccination age (60, 65, 
or 70 years) in 2016–2020, which is about 
25 years with initial vaccination at age 
60. Vaccine uptake of 30 % was assumed 
based on the situation in Germany as of 
the time of writing.
. Table 11 shows the results for the 
base case. . Table 12a shows the results 
of a sensitivity analysis on the assump-
tion of 0 % efficacy of PPSV23 against PP 
(with PCV13 efficacy unchanged). . Ta-
ble 12b and c show the results for these 
two scenarios on the additional assump-
tion that PCV13 is as effective against ST 
3 as against the other vaccine serotypes, 
while PPSV23 is half as effective against 
ST 3 (in . Table 12c, only against IPD). 
Results of vaccination strategies 
with one-time vaccination
The results show that the vaccination of 
older adults with PPSV23 can, on the 
whole, prevent more cases, and the num-
bers needed to vaccinate (NNV) to pre-
vent hospitalisation or death are lower 
than for vaccination with PCV13. There-
fore, PPSV23 is the superior choice for a 
vaccination strategy with one vaccine only.
One-time vaccination with PPSV23 
results in NNVs to prevent one hospi-
talisation with IPD or PP in the range of 
648–801, depending on age at vaccina-
tion. NNVs to prevent one death range 
from 4,247 to 6,690. Few additional cas-
es could be prevented by sequential vac-
cination with PCV13 + PPSV23. In the 
base case, depending on age at vaccina-
tion, about 3,500–6,100 older adults must 
be vaccinated with PCV13 in addition to 
PPSV23 to prevent one additional hospi-
talisation, and 18,000–38,000 to prevent 
one additional death. In contrast, dou-
bling the PPSV23 vaccine uptake in old-
er adults from the current c. 30 % to 60 % 
could roughly double the number of pre-
vented cases. 
Results of vaccination strategies 
with repeated vaccinations
Because of the limited duration of protec-
tion provided by PPSV23, and the lack of 
a booster effect, repeating the vaccination 
at regular intervals appears plausible. The 
duration of protection and the frequency 
and severity of side effects must be taken 
Table 8 Selection criteria for studies on the efficacy and reactogenicity of repeated vaccina-
tion with PPSV23
Population  5 Persons 60 years and over, healthy or with age-typical underlying 
disease (expanded search for adults age ≥50 years, depending 
on data available)
 5 Countries/populations with living conditions comparable to 
those in Germany
Intervention  5 Repeat vaccination with PPSV23
Comparator intervention  5 First time vaccination with PPSV23
Endpoints  5 Clinical endpoints: Invasive pneumococcal diseases (IPD), Pneu-
mococcal pneumonia (with inpatient treatment)
 5 Immunogenicity 
 5 Mean ELISA antibody levels (geometric mean concentrations, 
GMCs), opsonophagocytic indices
 5 Safety/reactogenicity 
 5 Fever >38°C (>100°F) ≤14 days after the vaccination, unplanned 
medical visits ≤14 days after the vaccination, headache, malaise, 
muscle and/or joint pain, severe local reactions: pain, impaired 
arm movement
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into account in defining the vaccination 
interval. Intervals <6 years were not mod-
elled because more side effects are to be 
expected with shorter intervals.
The calculations in . Table 11 and 12. 
are based on the assumption that re-vac-
cinations have the same efficacy as the in-
itial vaccination, and that all people who 
receive the initial vaccination (30 % of 
each age cohort) receive re-vaccinations 
at the defined intervals for the rest of their 
lives.
Because the risk of falling ill with a 
pneumococcal infection increases with 
age, both the individual and epidemio-
logical benefits of vaccination increase 
with age. Thus, the sum of re-vaccina-
tions can prevent far more cases than 
one-time vaccination, and the NNVs 
are markedly lower. That also applies to 
a sensitivity analysis on the assumption 
that repeat vaccinations are only 75 % as 
effective as the initial vaccination (data 
not shown).
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(ICD-9 codes)







USA Resident population 
≥65 yrs
66,256/1,099 not reported 
clearly, 
<1 to >3 yrs
Safety only 
(hospital admis-



















USA Alaska native popu-
lation, 
72 % ≥60 yrs
144/35 (2nd dose) 
and 179 (≥3rd 
dose)
45 % ≥6 yrs, 
55 % <6 yrs
Safety only 
(ICD-9 codes, chart 
review)
Funded in part by Associ-
ation of Schools of Public 
Health
CAP community acquired pneumonia, COPD chronic obstructive pulmonary disease, ELISA Enzyme-Linked Immunosorbent Assay, OPA Opsonophagocytic Activity assay; 
Prosp. prospective, WHO World Health Organization, WHO-ELISA ELISA according to WHO consensus protocol 
a: In some studies, some analyses (e. g. safety) were conducted in a smaller subpopulation. 
b: Published as randomized controlled trial but treated as cohort study here. 
c: Not all patients were considered for all endpoints. 
d: Sub-study of Musher, 2010 
e: Number of participants at 5 yrs: 159/181. Only the results for the sub-group of ≥ 65 year olds were considered for this analysis. 
f: Extension study of Musher, 2010
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The effects resulting from an initial 
sequential vaccination with PCV13 and 
PPSV23, instead of PPSV23 alone, were 
also modelled. In the base case and in 
scenarios shown in . Table 12a and b, 
sequential vaccination can prevent only 
around 2–20 additional hospitalisations 
and 1–3 additional deaths per year, with 
very high NNVs and costs per quali-
ty-adjusted life year (QALY). Only in the 
scenario in . Table 12c, sequential vac-
cination leads to noteworthy numbers of 
additional prevented hospitalisations and 
deaths, with reasonable NNVs and costs 
of <€ 100,000 per QALY. This scenar-
io assumes a lack of efficacy of PPSV23 
against non-bacteraemic PP and low-
er efficacy against ST 3 for PPSV23, but 
not for PCV13. STIKO considers this 
scenario highly improbable for the rea-
sons given in Sect. 4 and 6.2. The scenar-
io was modelled to get an impression of 
how drastic the assumptions in favour of 
PCV13 need to be to achieve reasonable 
NNVs and costs per QALY for the se-
quential vaccination. 
Health economic evaluation
Assuming a vaccine uptake of 30 % of 
each cohort reaching age 60 (or 65 or 70) 
in 2016–2020, and taking into account the 
direct and indirect costs (work lost), the 
various vaccination strategies result in the 
figures shown in . Table 11 and 12.
In the base case (. Table 11), the costs 
for a one-time vaccination with PPSV23, 
depending on age at vaccination, are 
about € 17,100–18,800 per hospitalisa-
tion prevented, and € 14,400–15,700 per 
QALY gained. The vaccination strate-
gy with PPSV23 dominates PCV13; i. e. 
one-time vaccination with PPSV23 pre-
vents more hospitalisations and deaths at 
lower costs than one-time vaccination with 
PCV13. That is true even if lacking efficacy 
of PPSV23 against PP is assumed (. Ta-
ble 12a).
The costs of sequential vaccination 
with PCV13 + PPSV23 are very high: in 
the base case € 216,000–375,000 per ad-
ditional prevented hospitalisation and 
€ 306,000–366,000 per additional QALY 
gained. In the scenario that assumes no 
efficacy of PPSV23 against PP (. Ta-
ble 12a), the costs of sequential vaccina-
tion per additional prevented hospitali-
sation and QALY gained are still around 
2–4.5 times higher than those of vaccina-
tion with PPSV23 alone.
In the vaccination strategies with re-
peated PPSV23 vaccinations, the differ-
ences between the two strategies (initial 
vaccination with PPSV23 alone vs. initial 
sequential vaccination) are even greater. 
In the base case, vaccination with PPSV23 
alone would incur costs of about € 6,700–
6,900 per hospitalisation prevented, and 
€ 12,000–13,000 per QALY gained. The 
costs of sequential vaccination, howev-
er, are extremely high: € 426,000 to € 2.8 
million per additional hospitalisation pre-
vented and QALY gained, respectively.
Table 10 Assumptions for modelling (base case)
Parameter Value assumed Based on
Vaccine uptake among seniors 30 % DEGS study [15]
Efficacy of PPSV23
 5 against VT-PP 66.5 %* Own meta-analysis of RCTs (. Fig. 5)
 5 against VT-IPD 75.0 %* Own meta-analysis of RCTs (. Fig. 5)
 5 duration of protection ** IPD: 4.7 years 
CAP: 3.8 years
Modelled based on the results of RCTs and 
cohort studies
 5 against serotype 3 Half efficacy see Sect. 4
Efficacy of PCV13
 5 against VT-PP 45.9 %* CAPITA study [22]
 5 against VT-IPD 76.6 %* CAPITA study [22]
 5 duration of protection ** 8.2 years CAPITA study and English data on the 
duration of protection in children [78]
 5 against serotype 3 Half efficacy see Sect. 4
Incidence of IPD Age-dependent Result of the dynamic transmission model 
for Pnc carriers in consideration of infant 
vaccination since 2006, based on German 
data on IPD incidence before the introduc-
tion of infant vaccination [116, 117]
Incidence of PP Age-dependent Incidence data from federal health reports 
and IMS-Health, estimated percentage of 
PP among all CAP cases 20 % [33]
Case fatality Age-dependent Based on serotype-specific English data 
[118], adjusted to serotype mix and age 
structure in Germany
Serotype mix Dependent on 
calendar year
Result of dynamic transmission model, 
serotyping results of the National Refe-
rence Centre for streptococci
Disease costs per case
 5 IPD € 8,581 DRG browser 2012/2014
 5 CAP, inpatient treatment € 3,178 DRG browser 2012/2014
Vaccine prices 
(per dose, pack of 10)
 5 PPSV23 € 29.08 Lauer scale of charges 15 October 2015
 5 PCV13 € 60.24 Lauer scale of charges 15 October 2015
 5 Vaccination fees € 7.19 Average of vaccination agreements
Discounting 3 %
* Initial vaccination efficacy, reduction over time was taken into account in the model. Values for PPSV23 apply to 
cases caused by any serotype, but were used in the model as efficacy against cases caused by vaccine serotypes 
(VT) to provide a conservative model.
** The period of protection shown is an arithmetical mean that takes the waning of protection over time into 
account.
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7. Conclusions
STIKO examined its existing recommen-
dation for pneumococcal vaccination of 
older adults with regard to the question 
which of the possible vaccination strat-
egies (vaccination with PPSV23, vacci-
nation with PCV13, sequential vaccina-
tion PCV13 + PPSV23) is preferable, or 
whether an infant vaccination programme 
alone (without vaccination of older adults) 
is sufficient from an epidemiological per-
spective. STIKO also investigated whether 
the vaccination age should be raised from 
the current 60 years, and whether repeat-
ed vaccinations should be recommended.
There is no evidence available from a 
direct comparison of the efficacy of the 
two available vaccines. Data from RCTs 
and observational studies in which ei-
ther PPSV23 or PCV13 were investigat-
ed in comparison with no vaccination or 
placebo indicate no significant differences 
in efficacy between the two vaccines in the 
protection they provide against IPD and 
pneumococcal pneumonia caused by the se-
rotypes contained in the respective vaccine.
However, the confidence intervals 
of the efficacy estimates against IPD are 
so wide that a clinically relevant efficacy 
difference between PCV13 and PPSV23 
against vaccine serotype disease cannot be 
ruled out with certainty. With regard to re-
actogenicity, RCTs with a direct compari-
son of the two vaccines did not show any 
significant differences either, except for a 
slightly higher occurrence of muscle pain 
after PPSV23.
Crucial to the choice of the most effec-
tive vaccination strategy is the fact that the 
proportion of PCV13 serotypes in disease 
cases in all age groups has dropped sig-
nificantly through herd protection pro-
vided by PCV13 vaccination of infants. In 
the 2015–’16 season, only 30 % of IPD cas-
es in people aged ≥60 years were caused by 
PCV13 serotypes, while 70 % were caused 
by PPSV23 serotypes. In light of this sero-
type distribution, the protection from in-
vasive pneumococcal diseases achievable 
through vaccination with PCV13 – re-
gardless of the vaccination’s efficacy – is 
greatly limited from the outset. Hardly any 
data on serotype distribution of PP with-
out bacteraemia in adults are available. A 
Danish study suggests the percentage of 
both PCV13 and PPSV23 serotypes may 
Table 11 Preventable cases, NNV and costs of various vaccination strategies. Vaccination of persons who will reach vaccination age (60, 65, or 
70 years) in 2016–2020. Base case
Cases prevented 
(Cumulative for the remaining lifespan of individuals 
vaccinated)
















60 years 1,505 748 270 801 6,690 € 18,838 € 14,383
65 years 1,440 700 298 725 5,208 € 19,634 € 15,670
70 years 1,357 627 303 648 4,247 € 17,056 € 15,436
PCV13 alone (one-time)
60 years 454 271 101 2,490 17,931 € 149,338 € 112,606
65 years 463 265 119 2,134 13,026 € 129,327 € 100,829
70 years 519 236 137 1,703 9,411 € 102,370 € 96,372
Sequential vaccination (one-time PCV13 + PPSV23) 
additional preventable cases and additional necessary vaccinations with PCV13, compared to vaccination with PPSV23 alone
60 years 186 110 47 6,072 38,024 € 375,498 € 366,499
65 years 212 113 56 4,762 27,438 € 293,721 € 318,812
70 years 273 90 71 3,521 17,960 € 216,506 € 306,411
Initial vaccination with PPSV23 at age 60 years and re-vaccinations with PPSV23 
(compared to no vaccination)
every 6 years 17,898 4,271 4,272 398 2,064 € 6,690 € 12,839
every 8 years 13,734 3,424 3,267 396 2,077 € 6,685 € 12,294
every 10 years 11,026 2,826 2,650 403 2,104 € 6,880 € 12,195
Sequential vaccination at age 60 years and re-vaccinations with PPSV23 
additional preventable cases and additional necessary vaccinations with PCV13, compared to vaccination with PPSV23 alone
every 6 years 47 24 11 25,038 167,139 € 1,561,736 € 2,810,187
every 8 years 120 70 29 9,471 61,333 € 587,983 € 598,592
every 10 years 160 95 40 7,052 45,011 € 436,714 € 425,785
NNV  Number needed to vaccinate, QALY quality-adjusted life year 
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be lower than in IPD cases, with a simi-
lar ratio between the two serotype groups.
In light of the above, the epidemiologi-
cal effects of various vaccination strategies 
(PPSV23, PCV13, and sequential vaccina-
tion) were examined in a dynamic trans-
mission model. This showed that in the 
base case, considerably more cases of IPD 
and PP can be prevented through vaccina-
tion with PPSV23 than through vaccina-
tion with PCV13. Sequential vaccination 
with PCV13 + PPSV23 prevents only very 
few additional cases at very high costs.
If in the 5-year period of 2016–2020, ac-
cording to the current vaccine uptake, 30 % 
of people who reach 60 years are vaccinat-
ed with a single dose of PPSV23, an esti-
mated cumulative total of 2,253 hospitali-
sations and 270 deaths from pneumococcal 
diseases can be prevented in their lifetimes, 
compared to no vaccination (NNV: 801 
per hospitalisation, 6,690 per death). If the 
vaccine uptake were doubled, the num-
ber of hospitalisations and deaths prevent-
ed would also roughly double, while the 
NNV would remain the same. Additional 
vaccination with a single dose of PCV13 
would prevent a cumulative total of only 
296 further hospitalisations and 47 further 
deaths; i. e. around 5–7 times more vac-
cinations with PCV13 than with PPSV23 
were needed to prevent one additional hos-
pitalisation or one additional death.
A significant limitation of the efficacy 
of pneumococcal vaccination is the limit-
ed duration of protection. For that reason, 
STIKO also analysed the evidence on effi-
cacy and reactogenicity of re-vaccinations 
with PPSV23. In the first 2 months after 
a second vaccination with PPSV23, anti-
body levels were lower than in the first 2 
months after the initial vaccination. How-
ever, 1–10 years after re-vaccination anti-
body levels were as high or even higher 
than 1–10 years after the initial vaccina-
tion. That might mean that re-vaccination 
provides somewhat lower protection than 
the initial vaccination. To our knowledge, 
there are no studies with clinical end-
points examining this question. 
Because the risk of contracting a pneu-
mococcal infection increases with age, 
both the individual and epidemiological 
benefit of vaccination increase with age. 
That leads to lower NNVs and costs per 
case prevented for re-vaccinations, even if 
a 25 % lower efficacy than for the initial 
vaccination is assumed. 
The costs of a vaccination strategy con-
sisting of initial and re-vaccinations with 
Table 12a Sensitivity analysis with 0 % efficacy of PPSV23 against PP
Cases prevented 
(Cumulative for the remaining lifespan of individuals 
vaccinated)
















60 years 0 748 128 2,413 14,063 € 72,085 € 37,746
65 years 0 700 146 2,217 10,627 € 67,244 € 36,344
70 years 0 627 144 2,051 8,903 € 61,403 € 37,549
PCV13 alone (one-time)
60 years 454 271 101 2,490 17,931 € 149,338 € 112,606
65 years 463 265 119 2,134 13,026 € 129,327 € 100,829
70 years 519 236 137 1,703 9,411 € 102,370 € 96,372
Sequential vaccination (one-time PCV13 + PPSV23) 
additional preventable cases and additional necessary vaccinations with PCV13, compared to vaccination with PPSV23 alone
60 years 454 110 72 3,187 24,889 € 192,859 € 178,595
65 years 463 113 83 2,684 18,681 € 163,898 € 163,370
70 years 519 90 99 2,098 12,854 € 127,421 € 153,893
Initial vaccination with PPSV23 at age 60 years and re-vaccinations with PPSV23 
(compared to no vaccination)
every 6 years 0 4,271 1,359 2,064 6,485 € 43,657 € 40,730
every 8 years 0 3,424 1,076 1,982 6,308 € 42,600 € 38,642
every 10 years 0 2,826 868 1,974 6,426 € 43,186 € 38,338
Sequential vaccination at age 60 years and re-vaccinations with PPSV23 
additional preventable cases and additional necessary vaccinations with PCV13, compared to vaccination with PPSV23 alone
every 6 years 454 24 66 3,761 27,087 € 234,936 € 247,730
every 8 years 454 70 77 3,433 23,262 € 213,880 € 207,647
every 10 years 454 95 84 3,275 21,472 € 203,719 € 191,253
NNV  Number needed to vaccinate, QALY quality-adjusted life year 
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PPSV23 alone and a sequential strategy 
(initial vaccination with PCV13 + PPSV23, 
re-vaccinations with PPSV23) were com-
pared. In both strategies, initial vaccina-
tion is assumed to occur at age 60 years. In 
the base case, the costs of the PPSV23-on-
ly strategy were € 6,700 per hospitalisation 
prevented, and € 12,800 per QALY gained. 
Thus, vaccination of older adults with 
PPSV23 (applied to costs per QALY) is 
clearly more cost-effective than, for exam-
ple, rotavirus vaccination of infants (about 
€ 120,000 per QALY [119]). The strategy of 
sequential initial vaccination would incur 
extremely high additional costs of about 
€ 1.5 million per hospitalisation prevent-
ed, and € 2.8 million per QALY gained.
Based on these findings and considera-
tions, STIKO continues to recommend vac-
cination with PPSV23 for all adults at age 60 
years. Additionally, STIKO considers re-vac-
cinations with PPSV23 with an interval of 
≥6 years useful from a medico-epidemiolog-
ical perspective to maintain vaccine protec-
tion. The current prescribing information of 
PPSV23 limits re-vaccination to “persons at 
increased risk of severe pneumococcal dis-
ease.” The indication for re-vaccination of 
healthy older adults should therefore be 
evaluated individually. Sequential vaccina-
tion with PCV13 and PPSV23 is not recom-
mended as a standard vaccination for older 
adults because of the low number of addi-
tional preventable cases, very high NNV, 
and high additional costs.
Acceptance of PPSV23, in particular 
of re-vaccinations, could be impaired by 
the known reactogenicity of the vaccine. 
Based on the available data, reactions to 
the vaccination (e. g. painful local swell-
ing, headache, pain in the limbs) appear 
to occur more frequently after re-vac-
cinations than after the initial vaccina-
tion. Vaccinees must be informed of this. 
Stronger reactogenicity was observed espe-
cially at intervals of <5 years between vac-
cinations. At intervals of >5 years, time be-
tween vaccinations appears to not further 
influence the frequency and severity of 
adverse events. Furthermore, these reac-
tions mostly appear to last only 2–3 days, 
as controlled studies have shown. 
In STIKO’s opinion the balance of ben-
efits (protection from a severe disease with 
considerable case fatality) and risks of vac-
cination (painful side effects of limited 
duration) clearly favours repeated vacci-
nations. STIKO advocates accompanying 
implementation of this vaccination rec-
ommendation with a reactogenicity study 
Table 12b Sensitivity analysis with half efficacy of PPSV23 against ST 3 and full efficacy of PCV13 against ST 3
Cases prevented 
(Cumulative for the remaining lifespan of individuals 
vaccinated)












IPD Deaths Hospitalization 
(PP or IPD)
Death
PPSV23 alone (one-time) vs. no vaccination
60 years 1,505 748 270 801 6,690 € 18,838 € 14,383
65 years 1,440 700 298 725 5,208 € 19,634 € 15,670
70 years 1,357 627 303 648 4,247 € 17,056 € 15,436
PCV13 alone (one-time) vs. no vaccination
60 years 813 485 188 1,391 9,613 € 80,499 € 59,102
65 years 841 480 221 1,175 7,029 € 69,128 € 53,717
70 years 962 430 256 924 5,014 € 53,584 € 50,582
Sequential vaccination (one-time PCV13 + PPSV23) 
additional preventable cases and additional necessary vaccinations with PCV13, compared to vaccination with PPSV23 alone
60 years 502 324 130 2,175 13,788 € 130,323 € 101,032
65 years 546 327 153 1,768 10,077 € 106,065 € 90,647
70 years 672 284 186 1,335 6,870 € 79,447 € 85,310
Initial vaccination with PPSV23 at age 60 years and re-vaccinations with PPSV23 
(compared to no vaccination)
every 6 years 17,898 4,271 4,272 398 2,064 € 6,690 € 12,839
every 8 years 13,734 3,424 3,267 396 2,077 € 6,685 € 12,294
every 10 years 11,026 2,826 2,650 403 2,104 € 6,880 € 12,195
Sequential vaccination with PPSV23 at age 60 years and re-vaccinations with PPSV23 
additional preventable cases and additional necessary vaccinations with PCV13, compared to vaccination with PPSV23 alone
every 6 years 246 183 66 4,191 27,101 € 255,020 € 179,637
every 8 years 372 246 95 2,910 18,913 € 175,743 € 129,773
every 10 years 450 294 116 2,415 15,533 € 145,118 € 109,942
NNV Number needed to vaccinate, QALY quality-adjusted life year 
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to examine whether the frequency and 
severity of the reactions after re-vaccina-
tions in practice are in the same range as 
expected based on published data.
To enhance the epidemiological effects 
of the PPSV23 vaccination recommenda-
tion, a significant increase in vaccine up-
take among older adults from the current 
30 % is desirable. To address this, the rea-
sons for the low vaccine uptake especially 
in the states of the former West Germa-
ny should be established, and acceptance 
of the vaccination should be increased 
through customised measures. Vaccine 
uptake in the target group needs to be 
tracked regularly to evaluate such meas-
ures. Furthermore, there is urgent need 
to continue laboratory-based surveillance 
of serotype distribution in IPD cases, and 
expand it to include studies of serotype 
distribution in non-bacteraemic pneu-
mococcal pneumonia. Understanding 
the serotype distribution is an indispen-
sable prerequisite for effectively assessing 
various vaccination strategies, also with 
regard to the higher-valent pneumococ-
cal conjugate vaccines expected in the fu-
ture.
STIKO recommendations on risk-
based vaccination of people with certain 
underlying diseases were not part of this 
evaluation. Updated STIKO recommen-
dations for risk-based vaccination against 
pneumococci can be found in the revised 
table 2 of the STIKO recommendations. 
The scientific rationale for these recom-
mendations has been published separate-
ly (in Epid Bull 37/2016, in German).
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Appendix
Fig. A1 9 Flow chart for 
the systematic literature 
search on the efficacy/ef-
fectiveness of a one-time 
vaccination with PPSV23 
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Fig. A2 9 Flow chart for 
the systematic literature 
search on the safety and 




(elderly OR adult* OR (old*adult*)) AND 
(pneumococc*[title/abstract] AND vac-
cin*[title/abstract] NOT (10-valent[title/
abstract])) AND (safety[title/abstract] OR 
reactogenicity[title/abstract] OR (adverse 
event*[title/abstract])) NOT pediatr*[ti-
tle/abstract]
Search in Embase, Cochrane Central 
Register of Controlled Trials (CCTR), 
Cochrane Database of Systematic Re-
views (CDSR), Current Contents Medi­
zin (German language publications), 
MEDLINE 
via DIMDI:
SBAS EM10; CCTR93; CDSR93; CCMed; 
ME10
find ft = (elderly OR adult? OR (old-
?,adult?))
find ft = (pneumococc? AND vaccin?)
find ft = (safety OR reactogenicity OR (ad-
verse event*))
Find 2 AND 3 AND 4
Find 5 AND LA = (GERM;ENGL;ITAL;-
FREN;SPAN)
CH dup  (automatic removal of dupli-
cates)
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